Angiograms

function. 1069(ab)

Angiograms coronary
TI-201 stress test. 1377(ab)

Angiography, radionuclide
cardiac malposition
adults, 484
detection of gastrointestinal bleeding
carcinoid. 435(ab)
determining pressure-volume loops
clinical setting. 992(ab)
dosimetric aspects
tumor therapy. 1490

first pass
myocardial perfusion imaging. 927(ab)
first-pass, background correction. 1480
hepatic artery infusion pump. 1031(ab)
high count rate first-pass
digital gamma camera. 198
left ventricular diastolic function. 1908
left ventricular regurgitation
factor analysis and deconvolution. 1374(ab)
prognostic interpretation
exercise ejection fraction, wall motion. 934(ab)
prognostic value dependent upon diagnostic value. 926(ab)
pulmonary sequestration or tumor on. 726(ab)
renal artery flow. 575(ab)
right ventricular ejection fraction
children. 919(ab)
myocardial infarction. transfer function analysis. 968(ab)
screening for abnormal superior vena cava flow. 838

Angioplasty
balloon
platelet accumulation in. atherosclerosis. 103(ab)

Angiosarcoma
hepatic
red blood cell scintigraphy. 1861

Angiotensin-converting enzyme
renal function changes after
hypertension. 105(ab)

Animal rights movement
Animal rights movement undermines research
and threatens laboratories. N323

Anorexia nervosa
gastric emptying study in. 1072(ab)

Anthracycline cardiotoxicity
peak filling rate for detection. 1796(ab)

Antibiotics
sensitivity of In-111 leukocyte scans. 1849

Antibodies
antifibrin
In-111. imaging of vascular thrombi. 975(ab)
thrombosis imaging. Tc-99m. 975(ab)
infuional
reactivity to CEA. 1041(ab)
production of Zr-89
PET. 983(ab)
radiolabeled
tumor therapy. 1490
radiolabeling
Tc-99m. 99mTc, ligands. 957(ab)

Anticoagulation
occult hemorrhage
scintigraphic detection. 223

Antimyosin
DTPA-polylysine linked
myocardial infarction. 909(ab)

monoclonal
myocardial infarction. 1069(ab)

Apoplosis
I-131 MIBG imaging in. 1221(ab)

Arteriovenous malformations
cerebral blood flow
dSPECT determination of. 733(ab)

Arthritis
rheumatoid
In-111 leukocyte imaging. 339
rheumatoid and osteoarthritis
Ga-67 suprapatellar/thigh ratio. 989(ab)

Asbestos
Ga-67 uptake and lung. 338

Asciies
peritoneo-pleural communication. 1706

Asiato-transferrin
enhancement of Ga-67 uptake
hepatic. 395

Atherosclerosis
angioplasty
platelet accumulation in. 103(ab)
radiolabeling of metalloporphyrins for. 104(ab)

Atomic bomb survivor data
New dosimetry changes atomic bomb data. N1242

Atrial atrioventricular factor
renal plasma flow and. 571(ab)

Attenuation correction
area weighted approach
nonuniform attenuation maps. SPECT. 88(ab)
improved SPECT
simultaneous transmission and emission tomography. 88(ab)

Automated edge detection technique
intracoronary thrombolysis effects
global left ventricular function. 478

Automated gamma counter
thyroxi and free thyroxin assay. 1623

Autoradiography
characterization of Tc-99m-d,L-HM-PAO
rCBF imaging agent. 905(ab)
glucose metabolic rates
compared with C-14 glucose and F-18 fluorodeoxyglucose. 956(ab)
image analyzer
design/development/testing. 1000(ab)
multiple-radiouclide
cerebral blood flow tracer. 1074(ab)
quantitative
personal computer. 549
quantitative digital. 1018(ab)

Avascular necrosis
femoral head
comparison of RN/MRI/XCT imaging. 952(ab)
planar scanning and SPECT
femoral head. 952(ab)

Azophenylsazonate
mutant anti-ARS Mab
pharmacokinetics and imaging. 1023(ab)

B

Benzodiazepine
binding sitesrain. 1593

1,4-Benzodiazepine
radiodiiodinated
preparation and biodistribution. 1046(ab)

Berson. Solomon A.
Nuclear Medicine Pioneer Award conferred on Rosalyn S. Yalow and Solomon A. Berson:

Discovery of insulin antibodies in the 1950s led to radioimmunoassay. N745

Biella. Daniel R.

Biliary atresia
neonatal cholestasis
pitfalls in evaluation. Tc-99m. 931(ab)

Biliary disease
calculous
cholecytokinin cholecystigraphy. 882(ab)

Biliary obstruction
alteration of DISIDA kinetics. 937(ab)
cholecystography in. 1403

Biochemical profiles
changes during complete thyroid hormone deficiency
thyroectoy thyroid cancer patients. 1528

Biotin
derivatives
radiodiiodinated. synthesis of. 103(ab)

BiSmith-212
labeled anti-TAC monoclonal antibody
T-cell leukemia radioimmunotherapy. 897(ab)

Bladder
pressure
renographic function and. 573(ab)
radiation absorbed dose
F-18-fluoracro-2-deoxy-o-glucose. 899(ab)
walt absorbed dose
estimation of. 567(ab)

Blastomyctosis
diagnosis and follow-up
Ga-67 imaging. 1015(ab)

Bleomycin
ruthenium. cobalt, and copper characterization. 104(ab)

Blood-brain barrier
dementia
Ga-68 and PET. 1074(ab)
disruption
TI-201 DDC distribution and. 736(ab)
permeability
error in parameter estimates. 1024(ab)
noninvasive measurement. 1024(ab)

Blood flow
tarterial time-activity curves. 100(ab)
assessment of coronary reserve
PET compared to coronary arteriography. 943(ab)
bone marrow
polychromatia vera. O-15 labeled carbon dioxide. 946(ab)

CBF measurements
Kety-Schmidt single-compartment model
PET. 913(ab)
cerebral
agent and MAO indicator. PET. 1048(ab)
agents for. PET. 532
alternation in simple phobic anxiety. O-15-
H2O PET. 901(ab)
cerebral vascular disease. SPECT assessment. 1005(ab)
chronic cocaine users. PET. 921(ab)
comparison of PET images. 1004(ab)
DPECT determination. arteriogenous malformations and. 733(ab)
imaging. acetazolamide enhancement of
HIPDM. 1627
imaging. Tc-99m complexes. 1050(ab)
IMP measurement. ischemia. 1028(ab)
ischemia. misosidazole uptake in. 1026(ab)
labeled amine perfusion agent uptake and
cerebellum. 1028(ab)
seizures or hallucinations, 1-123 IMP, 1029(ab)
SPECT, 465
SPECT determination, schizophrenic patients, 732(ab)
SPECT imaging, Tc-99m HM-PAO, early
detection of cerebral infarction, 888(ab)
SPECT study of, 732(ab)
Tc-99m-d1-HM-PAO, 1050(ab)
cerebral tracer
1-123 HIPDM kinetic model, 941(ab)
chronic cerebral infarcts
1-123-lodo amphetamine and Xe-133 SPECT,
PET, 888(ab)
evolution tomographic data from, 917(ab)
determination of LCBF
formation of partial seizures, temporal lobe
epilepsy, 902(ab)
forearm
radionuclide assessment of peripheral
hemodynamics, 192
hepatic artery and portal vein
quantitative measurement, deconvolutional
analysis, 957(ab)
improvement in coronary flow reserve
coronary angioplasty, PET, 977(ab)
isonitrile ester complexes of technetium, 894(ab)
liver
progressive cirrhosis effects, 1751
measurement of rCBF by SPECT
Tc-99m HM-PAO, 905(ab)
myocardial
high resolution scintigraphy, excised heart, 1586
hypertrophic cardiomyopathy, PET, 933(ab)
1-123, 1048(ab)
Rb-82 and PET, 976(ab)
myocardial perfusion
imaging with Tc-99m SQ 30217, 893(ab)
novel method to measure regional cerebral blood
flow, 912(ab)
O-15 butanol
preparation for positron tomography, 834
perfusion and receptor SPECT in the dementias
George Taplin Memorial Lecture, 855
regional liver
inhalation of Xe-133, 1012(ab)
renal
cortex perfusion index, transplant rejection
analysis, 1697
renal vascular transit time
Tc-99m compounds, 1006(ab)
screening
superior vena cava obstruction, 838
simultaneous measurement
oxygen utilization, 913(ab)
skeletal muscle
maximum and submaximum exercise, heart
failure, 99(ab)
stability of O-15 steady state technique, 912(ab)
Tc-99m HM-PAO as an agent for, 1031(ab)
Tc-99m HM-PAO marker, 905(ab)
TI-201 uptake and
global left ventricular, 641
"three phase" bone scan
diagnostic information in bone scintigraphy,
98(ab)
TI-201 diethylidithiocarbamate as tracer, 913(ab)
uetanic phase imaging.
Sunbeet 15000(e)
Blood-pool imaging
coronary and noncoronary artery disease
regional wall abnormalities by phase analysis.

radionuclide angiograms, 781
first-pass radionuclide angiography
left ventricular volume measurement, 912(ab)
gastrointestinal bleeding site
detection in liver cirrhosis, 435(le)
gated critically ill, 722
hepatic hemangiomas
contribution of SPECT imaging, 925(ab)
labeling plasma proteins
Tc-99m labeled agent, radionuclide
ventriculography, 900(ab)
multiple ventricular tachycardia
scintigraphic evaluation, 989(ab)
noninvasive evaluation
pancreas allografts, 909(ab)
testicular torsion
scintigraphy, 1053(ab)
"three phase" bone scan
diagnostic information in bone scintigraphy,
98(ab)
uterine blush
multiphase bone imaging, 51
Board of Trustees
See Society of Nuclear Medicine (SNM)

Body contours
automated detection SPECT, 1184

Bone
angular deformity
scintigraphy, 103(ab)
benign disease
differentiation from benign bone disease, Tc-
99m MDP imaging, 727
bone loss rates
multiple cortical and trabecular skeletal sites,
885(ab)
chronic osteomyelitis
radiography, scintigraphy and CT, 978(ab)
cold bone defects
In-111 leukocyte scans, 977(ab)
comparison of Ga-67 scintigraphy and MRI
osteomyelitis, 978(ab)
degraded image quality
generator eluate contaminants, 1067(ab)
determining mineral content
importance for clinical use, 98(ab)
evaluation of mineral loss
hyperparathyroidism, single and dual
absorptiometry, 886(ab)
experimental hemarthrosis
joint scintigraphy with Tc-99m
pyrophosphate, 246
femoral head
avascular necrosis, comparison with RN/
MRI/XCT, 952(ab)
planar and SPECT scanning, avascular
necrosis, 952(ab)
giant cell tumor
radionuclide scanning, 329
In-111 leukocyte scans
hyperostosis frontalis interna on, 495
Tc-99m skeletal scintigraphy, infected total
hip prostheses, 977(ab)
infected diagnosis, In-111 granulocytes, 978(ab)
malignant otitis externa
comparison between SPECT and planar
imaging, Tc-99m MDP bone scan, 978(ab)
mass quantitizing techniques
transmission ultrasound, postmenopausal
osteoporosis, 908(ab)
metastases
I-131-labeled disphosphonates for, 1255
metastatic disease
Sr-89 therapy, 1030(ab)
mineral
dual photon absorptiometry measurements, 1362
mineral absorptiometric measurements
dual photon, accuracy, 906(ab)
mineral densitometric analysis
dissuse osteoporosis in paraplegics, 885(ab)
mineral density
comparison of spine and calcaneus, 907(ab)
measurements
comparison from different sites, 907(ab)
osteoporosis, 885(ab)
partial area analysis, dual photon
absorptiometry, 907(ab)
mineral scanners
Ga-153 sealed sources, 1067(ab)
normal loss
prediction of lumbar spine loss, dual photon
absorptiometry, 964(ab)
osteomyelitis
scintigraphy in, 566(le)
osteoporosis
response to medical therapy, 886(ab)
pathology
nuclear magnetic resonance proton imaging
of, 207
radionuclide imaging
hematogenous pyogenic osteomyelitis, 1680
186-Re(Sn)HEDP
new agent, metastatic carcinoma, 948(ab)
scanning
adductor insertion avulsion syndrome (shin
splints), 951(ab)
interpretation, stippled ribs and, 216
Tc-99m MDP uptake, normal lymph nodes, 988(ab)
scintigraphy
follow-up of prostatic carcinoma, 948(ab)
reflex sympathetic dystrophy, children, 932(ab)
skeletal disease
Tc-99m MDP whole body retention
measurements, 1067(ab)
skeletal scintigraphic findings
reflex sympathetic dystrophy, children, 932(ab)
skull scintigraphy
acute mastoid and ear infections, children, 989(ab)
Sm-153 chelates
biocalization, 915(ab)
spinal bone mineral
minimum detectable changes, 907(ab)
spontaneous and estrogen-caused changes
early postmenopausal women, 885(ab)
superiorostal formation
renal osteodystrophy, radiophosphate
disclosure, 1572
three-phase scan
diagnostic information in bone scintigraphy,
98(ab)
ischemia prior to injection, 1798(ab)
uptake of phosphonic acid analog of serine
Tc-99m-labeled, 847
vertebral and peripheral
age-, sex-, and menopause-related changes,
1540
Bone imaging
diphosphonate agents
severe systemic reaction to, 1432
Bone marrow
blood flow measurement
O-15 labeled carbon dioxide, polycythemia vera, 946(ab)

In-11 leukocyte scans
hyperostosis frontalis interna on, 495
involvement in lymphoma
magnetic resonance imaging, 964(ab)

**Book reviews**

Analytical and Chromatographic Techniques in Radio-pharmaceutical Chemistry, 1793
An Atlas of Normal Skeletal Scintigraphy, 730
An Introduction to Emission Computed Tomography, 1378
Atlas of Positron Emission Tomography of the Brain, 1505
Brigham and Women’s Hospital Handbook of Diagnostic Imaging, 1651
Cardiac Imaging and Image Processing, 1945
Diagnostic Nuclear Medicine: Patient Studies, 1946
Digital Image Processing in Radiology, 438
Dynamic and Compartimental Study of Adrenals Using Radiocholesterol In Vivo, 569
Essentials of Nuclear Medicine, 310
Induction of Thyroid Cancer by Ionizing Radiation (NCRP-80), 438
Information Processing in Medical Imaging, 1945
Lymphatic Imaging, Lymphography, Computed Tomography and Scintigraphy, 1506
Manual of Clinical Magnetic Resonance Imaging, 1505
Medical Reviews of Ionizing Radiation, 569
Miscellaneous Magnetic Resonance Imaging, 1631
NCRP Proceedings No. 6—Some Issues Important in Developing Basic Radiation Protection Recommendations, 730
NCRP Report No. 84, General Concepts for the Dosimetry of Internally Deposited Radionuclides, 1379
NCRP Report No. 83, The Experimental Basis for Absorbed-Dose Calculations in Medical Uses for Radionuclides, 1378
NMR in Living Systems, 1793
NMR Tomography and Spectroscopy in Medicine: An Introduction, 153
Nuclear Imaging in Pediatrics, 730
Nuclear Medicine in Clinical Urology and Nephrology, 310
Pediatric Nuclear Medicine, 152
Positron Emission Tomography, 1378
Positron Emission Tomography and Autoradiography—Principles and Applications for the Brain and Heart, 1793
Progress in Medical Radiation Physics, Volume 2, 1505
Radiological Physics, 1652, 1945
Sensitivity and Specificity of Common Scintigraphic Procedures, 152
The Elements of Graphing Data, 1794
The Selection and Performance of Radiologic Equipment, 569
The Visual Display of Quantitative Information, 1794

**Boron**
distribution analysis
alpha-autoradiography, 677
Boronic acids
adducts of technetium oxime complexes
myocardial imaging, 893(ab)

**Brain**
abscess
mecasiva, positive In-111 leukocyte scan, 60
amyotrophic lateral sclerosis

PET, cerebral glucose utilization, 920(ab)
arterial time-activity curves, 1001(ab)
astigmatic collimator for high sensitivity SPECT, 930(ab)
Bayes regression computation

glucose metabolism, stroke, 1004(ab)
benzodiazepine binding sites, 1593
blood-brain transfer of Tc-99m HMPAO
parietal cortex, 888(ab)

blood flow: see Blood flow, cerebral blood flow-to-volume SPECT, 465, 1938(ab)
C-11 dopa synthesis, 1046(ab)
caudate hypometabolism
Huntington’s disease, 920(ab)
cerebral glucose metabolism
normals, AIDS, and leukemia survivors, 945(ab)
cerebral metabolism
olivopontocerebellar atrophy, PET and 2-
FDG, 920(ab)

changes
aging and dementia, 735(ab)
chronic cerebral infarcts
123-I-lodo amphetamine and 133-Xe SPECT,
PET, 888(ab)
C-11 leucine cerebral protein synthetic rate
technical and modeling considerations, 955(ab)

C-11-4-methionine transport
double simple-probe detection system, 1026(ab)
correlative studies
1-123 IMP, 626
cystic tumors
P-32 therapy, 1503(ab)

3D display
emission tomographic data, 917(ab)
deoxyglucose-6-phosphate dephosphorylation
effects of diffusion limitation, 955(ab)
distribution of [5e-75]I-IMP

dopamine receptor agonists and antagonists,
900(ab)
dopamine D-1 and D-2 receptors
ligands C-11 SCH 23390 and C-11 raclopride,
879(ab)
dopamine receptor subtypes
differentiation, PET, 1026(ab)

3-D surface mapping
functional PET images, 918(ab)
edema
1-131 therapy for thyroid carcinoma and,
637
estimation of opiate receptor occupancy
dual detector system, 945(ab)
evaluation
11C-5-OH-PET method, 969(ab)
FDG model configuration

estimates of cerebral glucose metabolism,
940(ab)
functional development
5 days to 20 years of age, 901(ab)

functional imaging analysis
PET and SPECT, 946(ab)
functional relationships
mathematical/statistical approach, PET,
945(ab)

functional responses
beneath image resolution, PET, 1025(ab)
glucose metabolism
PET measurements of, 1358
glucose transport, 1867

glucose transport and phosphorylation
cerebellum, Alzheimer’s disease, 955(ab)
head tilt and effect on resolution orthogonal
transverse slices, 960(ab)

ibotenic acid lesioning
Alzheimer’s disease, 913(ab)

images
past as prologue, 1929
imaging agent
radioactive iodinated 8-OH-DPAT, 972(ab)
imaging of MPTP-induced change
turnover and damage to striatal dopaminergic, 879(ab)
IMP dynamics, 178
initial experience with Tc-99m HMPAO,
887(ab)
INQ and the muscarinic ACH-receptor system, 937(ab)
intra-arterial and intravenous [18F]BCNU
pharmacokinetics, evaluated by PET, 775
I-123 IMP
no-carrier-added synthesis via organoboranes,
1045(ab)
I-123-labeled isopropylamphetamine imaging
study of dementia, 761
measurement of CBF by SPECT
Tc-99m HM-PAO, 905(ab)

metabolic and hemodynamic studies of gliomas
PET, 889(ab)
metastatic melanoma
isopropl-1-123 IMP, 971(ab)
metastatic tumors
monoclonal antibodies in, 1028(ab)
neuroreceptor studies
simplified detection system, 184
new measurement method
regional cerebral blood flow, 912(ab)
no-carrier-added N-[18F]fluoroalklyspiroperidols
syntheses and biodistribution, 906(ab)

normal aging
dementia, MRI, 969(ab)
opiate receptor binding
cartenetain and, 1027(ab), 1027(ab), 1027(ab)
opportunistic infection
AIDS-related, Tc-99m DTPA, 498

partial complex seizures or hallucinations
1-123 IMP, 1029(ab)
perfusion and receptor SPECT in the dementias
George Taplin Memorial Lecture, 855
PET in brain aging and dementia, 945(ab)
positron camera
position-sensitive detectors, 90
potential imaging agents, 1054(ab)
preparation of F-18 fluoroethylpiperioine
evaluation as D-2 receptor ligand, 982(ab)

prominence of basal ganglia
metabolic activity in schizophrenia, 901(ab)
protein synthesis
L-tyrosine measurement, PET, 1049(ab)
protracters for mapping central catecholamine
stores, 1076(ab)
radiouclide imaging
reawakening of interest, 299
regional perfusion
SPECT, comparison with I-123 HIPDM,
1819
ring detector SPECT
improvement of spatial resolution, cerebral
blood flow, 1018(ab)
serial [18F]-methylspiroperidol (18F-NMS)
PET
antipsychotic drug D-2 receptor,
schizophrenics, 880(ab)
serotonin receptor radiotracer
PET, 983(ab)
simultaneous measurement
regional cerebral blood flow, oxygen
utilization, 91(ab)
2 kidney and 1 kidney Goldblatt hypertension, 961(ab)

Carbon-11
deuteroglucose alteration of biodistribution, 388
dopamine receptor tracer PET, 104(ab)

Radioimmunoassays PET, brain, 532

methionylglucose glucose transport, brain, 1867

MPTP tracer for Parkinson’s disease, 1600

Ro17-188 benzodiazepine binding sites in brain, 1593

Carbon-11 BCNU intra-arterial and intravenous pharmacokinetics, evaluated by PET, 775

Carbon-11 butanol N-13 glutamate uptake and perfusion effect of methotrexate, Waiker-256 carcinosarcoma, 970(ab)

Carbon-11 carbon dioxide PET method evaluation, brain, 969(ab)

Carbon-11 carfentanil binding to opiate receptors compartmental analysis with PET, 1027(ab) detection system, brain, 184 following sexual arousal, 1027(ab) graphical evaluation, 955(ab) temporal lobe epilepsy and, 1027(ab) estimation of opiate receptor occupancy dual detector system, 945(ab)

Carbon-11 deoxyglucose C-11 putrescine and cerebral malignancy, PET, 889(ab) effects of amphetamine local cerebral metabolism, 901(ab)

Carbon-11 depropanol turnover of MAO-B brain, 982(ab)

Carbon-11 dopa synthesis, 104(ab)

Carbon-11 leucine cerebral protein synthetic rate technical and modeling considerations, 955(ab)

Carbon-11-I-methionine transport brain, simple dual-probe detection, 1026(ab)

Carbon-11 methionine F-18-deoxyglucose and brain tumors, PET, 890(ab)

Carbon-11 N-methyl-keratanserin serotonin receptor radiotracer

radiosynthesis and biodistribution, 983(ab)

Carbon-11 N-methylpiperonol dopamine receptor binding effect of menstrual cycle, 1010(ab) dosimetry calculations neuroreceptor binding, 899(ab)

Carbon-11-3-N-(N-methylpiperonol dopamine receptor binding effect of lithium, 880(ab)

Carbon-11 putrescine C-11 deoxyglucose and cerebral malignancy, PET, 889(ab)

Carbon-11 SPECT 23390 study of dopamine receptors, 1047(ab)

Carbon-13 NMR mapping thiol redox status, 916(ab)

Carbon-14 glucose compared with F-18 fluordeoxyglucose glucose metabolic rate, autoradiography, 956(ab)

Carbon-14 oxalate estimation of plasma oxalate, 571(ab)

Carbon-14 tryptophan dual-tracer studies

HIPDM, pancreatic diseases, 957(ab)

Carciorniobryonic antigens (CEA) antibody radioimmunotherapy, colon cancer xenografts, 897(ab) assay clinical performance, 892(ab)

bifunctional antibodies with, 1041(ab) concealed epites radiolizing monoclonal antibodies, 1016(ab) I-123 labeled monoclonal anti-CEA fragments ECT detection of colorectal cancer, 880(ab) In-111 anti-CEA tumor imaging and surgical samples, correlation, 1023(ab)

Lewis-negative individuals, 1039(ab) radiotisady clearance patterns biodistribution and, 1072(ab) radiiodiodetection lung cancer, 881(ab) scintigraphic findings colonic cancer, 1021(ab)

Carcinoid tumors 1-131 MIBG imaging in, 1221(le)

Carcinoma thyroid diagnosis and staging with TI-201, euthyroid patient, 887(ab)

Cardiac output first-pass radionuclide determination region of interest selection effects, 1282

Cardiac shunts left-to-right radionuclide assessment, 1070(ab)

Cardiomyopathy hypertrophic regional myocardial blood flow, PET, 933(ab)

regional myocardial fatty acid uptake autoradiography, 933(ab)

Centocor Two biopharmaceuticals approved in Japan, 11450

Cerebellum malignancy C-11 putrescine and deoxyglucose, PET, 889(ab) white matter disorders PE, MRI and CT, 889(ab)

Cerebral blood flow comparison of PET images integrated projection technique, fixed distribution volume, 1004(ab) examination of assumptions PET, 1003(ab) imaging enhancement, acetazolamide, 968(ab) improvement of spatial resolution ring detector SPECT, 1018(ab) portable measurement system real diagnostics, 1017(ab)

Cerebral metabolic rate estimation PET using 2-FDG, 1070(ab)

Cerebral vascular disease blood flow-to-volume distribution SPECT, 465

Cerebritis
Cerebrospinal fluid

AIDS and detection by Tc-99m DTPA, 498
Cerebrospinal fluid injection radioactive distribution of thallium after, 1029(ab)
shunt assessment, 1025(ab)
Cerebrovascular disease PET and MRI comparison, 1026(ab)
Tc-99m HM-PAO SPECT, 888(ab)
Cerebrovascular diseases ischemic doppler-sonography and IMP spect, 1073(ab)
Chelating agents distribution of monoclonal antibodies and, 1746 double bifunctional, 1043(ab)
evaluation of granulocyte labeling, 1014(ab)
Chemotherapy evaluation of the effects 31P-NMR in glioma, 970(ab)
ostrogenic sarcoma Tc-99m HMIDP serial bone scans, 987(ab)
response Ga-67, oat cell carcinoma, 1032(ab)
Children nuclear medicine radiopharmaceutical dosage selection, 287
Choledectomy rim sign association, 353
Choledocystitis cholescintigraphy acaculostic biliary disease, 882(ab)
Cholescintigraphy bile duct obstruction, 1403
rubbenium-97-DISIDA, 1072(ab)
Choledasis neonatal hepatobiliary scintigraphy, 931(ab)
pitfalls in evaluation, Tc-99m, 931(ab)
Chromatography high performance liquid analysis of radioiodine, 1046(ab)
high pressure ion purification of reactor-produced F-18, 1047(ab)
Chromium-51 red blood cells storage period, 1014(ab)
Chromosomes aberrations following In-111 oxine leukocyte scintigraphy, 979(ab)
Chylothorax Tc-99m antimony sulfide colloid, 1783(le)
Cineangiography contrast left ventricular diastolic function, 1908
Circulation peripheral radionuclide assessment, 192
Cirrhosis liver detection of gastrointestinal bleeding site, 435(le)
progressive alterations in blood flow and reticuloendothelial function, 1751
Cisapride colonic transit in normal subjects scintigraphy, 4(ab)
gastric stasis, 5(ab)
scintigraphic evaluation dyspeptic patients, 904(ab)
Cisplatin N-13-labeled microscale synthesis, 399
tubular effects, 571(ab)
Cisternography isotope intracranial hypertension, 471
Cocaine chronic users cerebral blood flow, PET, 921(ab)
radioiodine binding human caudate, 1074(ab)
Coincidence system neuroreceptor studies brain, 184
Collitis ischemic In-111 neuphil imaging, 1782(le)
Collimator astigmatic convolution reconstruction algorithm, 896(ab)
high sensitivity SPECT, brain, 930(ab)
axial aperture in SPECT, 930(ab)
conventionally-designed converging validation, cone-beam SPECT, 930(ab)
efficacy of radionuclide thyroid scan evaluation of upper medistinal mass, intrathoracic goiter, 887(ab)
electronic high energy single photons, 931(ab)
fan beam design and clinical utility, SPECT imaging of head, 810
study of SPECT imaging, 930(ab)
four-quadrant multiple focused ring high performance single photon tomography, 733(ab)
high energy performance image oriented approach, 1799(ab)
low- and medium-energy comparison with I-123 antibodies, 1467
measurement of hole angulation camera head tilt, rotating camera SPECT, 96(ab)
moiré interference gamma camera quality assurance images, 820
performance evaluation automated high-resolution scanner, 1018(ab)
ring SPECT systems, 1017(ab)
selection SPECT brain imaging, 1729
slant-hole head tilt and effect on resolution orthogonal, transverse slices, SPECT, 960(ab)
Colon cancer In-111 anti-CEA Mab, 1021(ab)
prospective study of recurrence, I-131 B2T3, 1023(ab)
carcinoma radiocalization of xenografts, 1042(ab)
metastases immunoscintigraphy, Mab HT 29-15, 1023(ab)
transit in normal subjects cisapride effects, scintigraphy, 4(ab)
tumors In-111 benzyl EDTA, 1042(ab)
Colorectal cancer ECT detection I-123 labeled monoclonal anti-CEA fragments, 880(ab)
I-131 monoclonal antibodies comparison of route of administration, 902(ab)
Cyclophosphamide ovarian cancer and radioimmunoscintigraphy, practice and tumor uptake, 88(ab)
radioimmunoscintigraphy ECT compared to TCT, 880(ab)
Carcinoma ECT anti-CEA monoclonal antibody imaging, 1796(ab)
I-123 Fab fragments biokinetics, 1019(ab)
In-111 monoclonal antibody localization of, 1797(ab)
mastectomy In-111 CEA MoAB, 1075(ab)
Compton scatter correction by analysis spatially-dependent energy spectra, 960(ab)
Computer Council see Society of Nuclear Medicine (SNM)
Computers diagnostic software validation of, 436(le)
modeling planar myocardial perfusion imaging, 653
NEMA, ACR approve interface standards; SNM Computer Council surveys users, N101
Nuclear medicine community explores problems of computer/equipment market; SNM Computer Council considers formulating software guidelines, N585
personal quantitative autoradiography, 549
physical display and dictation station, 1797(ab)
physiological data gamma camera and, 1755
Computers, software Alzheimer's type correlates, 1024(ab)
arterial time-activity curves, 1001(ab)
artificial intelligence approach TI-201-3-D myocardial distributions, 1005(ab)
axial sampling density requirements PET, 1003(ab)
Bayes regression computation glucose metabolism in brain, stroke, 1004(ab)
circular harmonic transform algorithm PET and x-ray CT, 1003(ab)
SPECT reconstruction, 895(ab)
computer system for long term storage nuclear medicine data, 1002(ab)
dynamic arrhythmia filtration gated blood-pool imaging, 1347
dynamic SPECT hepatobiliary system, time-shifting, 980(ab)
FDG kinetic model mapping of rate constants, 1001(ab)
fully automated data processing PET studies, dopamine D-2 receptors, 1002(ab)
hepatic artery and portal vein blood flow quantitative measurement, deconvolutional analysis, 957(ab)
image calculator concept, 927(ab)
interpreting TI-201 images using fuzzy clustering, 928(ab)
inverse Monte Carlo image reconstruction SPECT, maximum likelihood estimation, 895(ab)
iterative attenuation correction in SPECT attenuation coefficients, transmission measurements, 1004(ab)
left-to-right shunts, 1069(ab)
localization of parathyroid tumors optimized dual-isotope, 962(ab)
low cost laser image
  high quality scintigraphic image, 1000(ab)
  mass attenuation and energy absorption
coefficients
  human tissues, gamma-ray energies, 1007(ab)
MRI pulse sequence parameters
  optimal tissue contrast, 281
new technique for analysis
dual radionuclide studies, 1005(ab)
nonstationary nonlinear filter
  scintigraphic images, 927(ab)
parathyroid imaging
  peak TI-201 activity, image reregistration
technique, 963(ab)
pattern recognition classification
cardiac LV RVWMA, radionuclide
  ventriculography, 927(ab)
quantitative SPECT, 1006(ab)
renal volume estimation
  SPECT, phantom study validation, 1006(ab)
screening for abnormal superior vena cava flow, 838
SPECT pre-reconstruction filtering, 1003(ab)
subtraction method
myocardial perfusion images, O-15 water and PET, 928(ab)
time-of-flight PET, 1000(ab)
treatment of axial data
  volume imaging, 917(ab)
use of germanium detector
  scatter correction in SPECT, 883(ab)
volume estimation in SPECT
  edge enhancement and volume projection, 917(ab)
  improved bone and gallium images, 988(ab)
Continuing medical education
  First international CME conference planned, N1390
Converting enzyme inhibition
  nitroprusside and, renal function changes in hypertension, 575(ab)
Copper-67
  antibodies labeled with, 1042(ab)
  therapeutic design of, 1041(ab)
Coronary artery
  TI-201 distribution and washout
  planar and SPECT techniques, 943(ab)
  TI-201 myocardial washout rate, 943(ab)
Coronary artery disease (CAD)
  assessment of dipyridamole TI-201 planar
  scintigrams, 944(ab)
  assessment of TI-201 late redistribution
  exercise myocardial SPECT, 900(ab)
Cardiology meeting in Japan examines PET applications in coronary artery disease:
  Kyoto University PET Center pursues routine clinical PET studies, N1383
  chest pain syndrome
  180° exercise TI-201, diagnostic accuracy, 999(ab)
coronary steal
  collateralized myocardium, noninvasive PET, 977(ab)
detection
  analysis of diastolic function, effect of age, 999(ab)
detection and localization
dipyridamole thallium images, 944(ab)
dipyridamole thallium imaging
  clinical decision making, 132
effect of eating
  TI-201 redistribution post ischemia, 953(ab)
effect of exercise position during stress testing
  cardiac and pulmonary thallium kinetics, 788
  evaluation of fatty acid uptake
  myocardial, 521
  exercise left ventricular ejection fraction
  men, exercise intolerance, 926(ab)
exercise radionuclide angiography
  prognostic value dependent upon diagnostic value?, 926(ab)
glutamate
  myocardial imaging agent in man, 891(ab)
  imaging with Tc-99m TBI, 9(ab)
  interpolating scan and oblique-angle tomograms
  myocardial PET, N-13 ammonia, 995(ab)
  interpreting TI-201 images using fuzzy clustering, 928(ab)
localization
  stress-redistribution TI-201 SPECT, 997(ab)
  measurement of left ventricular function
  ambulatory monitor, 911(ab)
  VEST, validation and variability, 1002(ab)
metabolic studies
  15-(ortho-I-123-phenyl)pentadecanoic acid, 891(ab)
  multicenter trial of In-111 antymyosin
  infarct-AVID imaging, 967(ab)
  myocardial imaging with Tc-99m T-BIN, 994(ab)
  positron cardiac imaging without a cyclotron
  Rub-82, diagnosis of coronary artery disease, 976(ab)
post infarct ischemia
  TI-201, 926(ab)
  radiolabeling of metalloporphyrins for, 1045(ab)
  regional wall abnormalities
  phase analysis, radionuclide angiograms, 781
  severely depressed left ventricle
  rest-redistribution TI-201, improvement after revascularization, 933(ab)
TI-201 myocardial scintigrams, quantitative analysis, 17
  TI-201 clearance
  peak exercise heart rate effects on, 26
  TI-201 myocardial imaging
  dipyridamole-induced coronary vasodilation, 31
  TI-201 uptake
  myocardial, sex-specific criteria for, 1837
  TI-201 distribution and washout
  dipyridamole, planar and SPECT techniques, 943(ab)
  TI-201 exercise testing
  after myocardial infarction, 967(ab)
  TI-201 ischemia
  significance of exertional angina, 998(ab)
  TI-201 myocardial washout rate, 943(ab)
  TI-201 SPECT
  assessment of coronary artery stenosis, before
  transluminal angioplasty, 944(ab)
  TI-201 testing of asymptomatic patients
  positive EKG tests, 99(ab)
  transaxial SPECT TI-201 perfusion imaging, 146(ab)
  viable myocardial segments
  PET, fixed thalium perfusion defects, 932(ab)
Correctors
  author addition, 870
diplomates certified by American Board of
  Science in Nuclear Medicine omitted from
  list, 729
error in editorial, 1944
error in text, 437(le), 1377(le), 1650(le)
reply to letter omitted, 1225
Corticosteroids
  potential ligand
  neuro-pet studies, , 1048(ab)
Credentialing
  HHS publishes credentialing rules, N328
Cycle-length windowing
  left diastolic ventricular function, 1068(ab)
Cyclosporin
  In-111 platelet imaging
  renal transplant rejection, 984(ab)
  In-111 platelet imaging
  renal transplant patients, 984(ab)
toxicity
  kidney transplants, patterns of rejection, 984(ab)
Cyclosporin A
  association with human serum proteins, 892(ab)
  I-123 accumulation
  renal transplant, 579(ab)
nephrototoxicity
  acute cellular rejection from, 578(ab)
  kidney transplant, 578(ab)
Cyclosporine renal arteriolopathy
directed therapy
  In-111 platelets, 964(ab)
Cyclotron
  small clinical design and performance, 1018(ab)
Cystography
  manometric quantitative nuclear comparison with x-ray cystography, 918(ab)
D
Dementia
  application of I-123-labeled isopropylamphetamine, 761
  brain aging and PET, 945(ab)
global cerebral and white matter changes, 735(ab)
multiple infarct diagnosis of Alzheimer’s disease, tomographic imaging of I-123 IMP, 769
normal brain aging and
  MRI, 969(ab)
pertusion and receptor SPECT
  George Taplin Memorial Lecture, 855
  perfusion patterns, 1939(le)
  regional cerebral blood flow
  SPECT, 732(ab)
2-Deoxy-2-fluoro-glucose
  variation of lumped constant substrate and hormone concentrations, 966(ab)
Deoxyglucose-6-phosphate
  dephosphorylation
  effects of diffusion limitation on kinetics, 955(ab)
Deoxynucleose study
  influence of plasma sampling times
  accuracy of estimation, input function, 999(ab)
Department of Energy (DOE)
  Congress approves DOE research budget, N16
Desmoid tumor
  Ga-67
  Gardner’s syndrome, 1032(ab)
Detector geometry
  wedgeshaped scintillation crystals
  positron tomography, 99
Deuterio-glucose
  alteration of biodistribution, 388
Dextrocardia
Diabetes

clinical evaluation by radionuclide angiography
adults, 484

Diabetes
gallbladder function and, 357
scintigraphic evaluation of gastric emptying of cardiac autonomic neuropathy, 1009(ab)

Diagnosis-related groups (DRGs)
yor Prospective Payment System (PPS)

Diazoxide
radioiodinated
determination of glomerular filtration rate, 45

Digoxin-like substance
termin pregnancy
newborns, and renal failure, 1418

Dimethylaminobutyric acid (HIDA)
hepatic infarction

transplant recipients, 1428

Diphosphonate
bone imaging agents
severe systemic reaction to, 1432

Dipyridamole
assessment of Ti-201 planar scintigrams, 944(ab)
coronary vasodilation induced by Ti-201 myocardial imaging, 31
thallium imaging
clinical decision making, 132
thallium uptake and blood flow relations myocardial, 641

Diuresis
renogram
quantitative assessment, 1053(ab)
DMSA scan
renal function and scarring, 582(ab)

Dopamine
receptors
F-18 FPSP binding to, 1047(ab)
Lesch-Nyhan syndrome, PET assessment, 102(ab)
receptor subtypes
differentiation using PET, brain, 1026(ab)

Dopamine receptors
binding of C-11 3-N-methylspiperone
effect of menstrual cycle, 1010(ab)

brain uptake of spiroperidol derivatives, 879(ab)
C-11 tracer PET, 1048(ab)
characterization
3-(2'-[F-18]fluoroethyl)spiperone, 879(ab)
C-11-SCH 23390 for study of, 1047(ab)

D-1 receptor site imaging agent, SKF-103108A biodistribution, 906(ab)

D-2 density, PET, 954(ab)
fully automated data processing, PET studies, 1002(ab)
ligand, preparation of F-18
fluoroethylspiperone, 982(ab)
D-1 and D-2
brain, ligands C-11 SCH 23390 and C-11 raclopride, 879(ab)
distribution of [Se-75]-pergolide
brain, 906(ab)
F-18 synthesis
mice, 226
lithium effect
C-11-3-N-methylspiperone, brain, 880(ab)
no-carrier-added N-[18F]fluoroalkylspiroperidol syntheses and biodistribution, 906(ab)
SPECT studies
2'-iodospiroperidol, 972(ab)

Dosimetry
biological distribution and uptake of Ti-99m MAA, 1008(ab)
comparison
radioimmunoassay and 4 MV external beam radiotherapy, tumor xenografts, 902(ab)
correction of I-131 uptake-vs.-time curves, 899(ab)
curative radioimmunotherapy novel strategy, 898(ab)
fetal
I-131, first month of pregnancy, 1007(ab)

HPS membership votes on committed dose, N328
internal
peritoneal cavity, 979(ab)
use of convolution integrals, 1799(ab)
mass attenuation and energy absorption coefficients
human tissues, gamma-ray energies, 1007(ab)
metabolic radiotherapy
I-131 MIBG, neuroblastoma and pheochromocytoma, 1008(ab)

Miniature sensor for measuring doses, N1818
neuroreceptor binding
radioisotope C-11 N-methylspiperone, 898(ab)
New dosimetry changes atomic bomb data, N1242

radiation
breast milk excretion of radioiodine and pertechnetate, 1569
cystic-type tumors, 1501(le)
estimation, bladder, 567(le)
radiocontaminants in I-123, 428
radioiodinated leukocytes, tracers for cell labeling, 979(ab)
tumor phantom models, 1308
tumor therapy, 1490

radiation absorbed dose profiles
renal transplant patients, 980(ab)
radiation absorbed dose
I-131 OIH, Tc-99m MAGs, 898(ab)
radioassay/radiation
on-line monitoring, 1038(ab)
radioiodinated monoclonal antibodies intraperitoneal delivery, 921(ab)

Biopharmaceutical dosimetry symposium
explores new internal dose estimates: Advances in nuclear medicine pose new reality, N163
radioiodinated derivatives selection
pediatric nuclear medicine, 287

TA-178 and W-178
adults and children, 1009(ab)
UK's Medical Research Council examines radiopharmaceutical microdosimetry, N1815

Down's syndrome
AFP radioassay method optimal clinical use at low levels, 893(ab)

Echocardiography

cardiac
U.S. hospitals (1983), 1635

Doppler comparison
right atrial time-activity curve analysis, tricuspid regurgitation, 992(ab)

Ectopic gastric mucosa
scintigraphy
glucagon improvement of Tc-99m pertechnetate, 1034(ab)

Editors

A reawakening of interest in radionuclide brain imaging, 299
Cardiovascular nuclear medicine—Training for the future, 1642
1986 Editor's report: Improvement and change, 1498
Gated blood-pool scanning in the critically ill: A valuable tool for clinical research, 722
Nuclear medicine in the prospective payment environment: The need for individual and group initiatives, 433

The changing climate in graduate medical education: Will it affect nuclear medicine?, 138

Effect
SNM initiates efficacy study of RIA tests and takes action on PET reimbursement; Board of Trustees endorses new standing committee on efficacy, N1238

Ejection fraction
cardiac response
ambulatory ventricular function monitor, 911(ab)
cholecoystokinin cholecintigraphy
acalculous biliary disease, 882(ab)
correlation of right and left ventricles volume measurements, 991(ab)
determining pressure-volume loops clinical setting, 992(ab)
exercise left ventricular men, exercise intolerance, 926(ab)
exercise radionuclide angiographic wall motion, prognostic interpretation, 934(ab)
gated cardiac blood pool studies
atrial fibrillation, cycle length windowing, 935(ab)
left ventricular volume measurement
first-pass radionuclide angiography, 912(ab)
measurement of left ventricular function
ambulatory monitor, 911(ab)
preservation of rest/exercise systolic/diastolic ventricular function
chronic alcoholics, 989(ab)
pressure-volume relationship
left and right ventricles, pacing-induced myocardial ischemia, 934(ab)
rest Ti-201 imaging
risk stratification, after acute myocardial infarction, 968(ab)

right ventricular
improving the technique, children, 919(ab)
myocardial infarction, transfer function analysis, 968(ab)
severely depressed left ventricle in ischemic heart disease
restricted-redistribution group, 934(ab)

Electrocardiogram (ECG) gating MR evaluation of anatomy
1.5T and 0.6T field strength, 985(ab)

Electrocardiography

exercise
prediction of death, myocardial infarction, and chest pain, 1842

Emission computed tomography
axial aperture in SPECT, 930(ab)
axial sampling density requirements
PET, 1003(ab)
Bayes regression computation

glucose metabolism in brain, stroke, 1004(ab)
brain imaging agent
radioactive iodinated 8-OH-DPAT, 972(ab)
comparison of spatial resolution
180° vs. 360° SPECT imaging, 1016(ab) coronary angiography
TI-201 tomography, 900(ab) 3D display
brain, 91(ab) extracranial thallium images
redistribution abnormalities, 997(ab) inverse Monte Carlo image reconstruction
SPECT, maximum likelihood estimation, 895(ab) modular focused collimator
transluminal angioplasty, 1017(ab) Monte Carlo simulations
experimentally measured scatter fractions, 960(ab) persons at-risk for Huntington’s disease
maximizing a posteriori likelihood, 920(ab) Kosinophils
role of radiography and scintigraphy
diagnosis and management of chronic osteomyelitis, 978(ab)
SPECT and functional imaging analysis, 944(ab) target detection, 1006(ab)
transluminal coronary angioplasty parameters
quantitative TI-201 tomography, 900(ab) treatment of axial data
volume imaging, 917(ab) Enteropathy
protein-losing scintigraphy, 1710 Enzyme inhibitors
radiolabeled, 1076(ab) Eosinophils
kinetics human body, 1014(ab) Epilepsy
brain imaging SPECT, CT, and NMR, 1028(ab) effects on neurotransmission
vitamin B-6 deficiency, 969(ab) temporal lobe
C-11 carfentanil, 1027(ab) evolution of partial seizures, determination of LCBF, 902(ab) Erythrocytes
membrane transport of pertechnetate, 946(ab) Esophagus
dysmotility pyloric obstruction, gastric decompression, 1011(ab)
retention, 916(ab) gastric stasis
cisapride effects, 5(ab) lower sphincter relaxation
forceful swallows with liquids, diagnostic procedure, 2(ab) transit test
respiratory effect, 6(ab) ulcers
Te-99m albumin sulphate, 1143 varices
pulmonary embolization, detection of focal perfusion following sclerotherapy, 956(ab) Estimators
maximum-likelihood estimation regional activity, 895(ab) Estrogen
bone changes early postmenopausal women, 885(ab) Estrogen receptors
affinity of BDPE, 972(ab) breast cancer, 305(e)
radiolabeled ligands
tissue distribution of 17α-[1-125]iodovinylestradiol derivatives, 939(ab)
synthesis of halogenated vinylcarbohydride and
vinylestradiol derivatives
cleavage of vinyl-tin bonds, 972(ab) 11β-Ethyl-17α-vinylestradiol
estrogen-receptor radiotracer, 916(ab) European Nuclear Medicine Congress
New European association rises to challenges facing nuclear medicine; European Nuclear Medicine congress examines clinical demands and efficacy, N1662
Oncology emphasizes strength of nuclear medicine in tissue characterization;
European Nuclear Medicine congress 1986 scientific highlights, N1653
Exercise
effect of position during stress testing
thoracic and pulmonary thallium kinetics, coronary artery disease, 788
TI-201 scintigraphic quantitation regional flow disparity, 75
Factor analysis
left to right cardiac shunts, 1442
Te-99m DTPA evaluation kidney transplant, 1025(ab)
tubular necrosis renal transplant, 1052(ab) Fatty acids
regional metabolism radiodinated 15-(p-iodophenyl)-3,3-
dimethypentadecanoic acid, 521 Fluronicine-18 fluorodeoxyglucose
Brookhaven, origin of Te-99m and F-18 FDG, opens new frontiers for nuclear medicine; LINAC's proton beam energies unique medical isotope producer, N1507
C-11 methionine and brain tumors, PET, 890(ab) caudate hypometabolism
Huntington's disease, 920(ab) cerebral glucose utilization, 940(ab) amyotrophic lateral sclerosis, 920(ab) cerebral metabolism
olivopontocerebellar atrophy, PET, 920(ab) compared with C-14 glucose
glucose metabolic rate, autoradiography, 956(ab) deoxyglucose-6-phosphate dephosphorylation
effects of diffusion limitation, 955(ab) effcient stereospecific synthesis, 235 functional development of brain
5 days to 20 years of age, 901(ab) glucose utilization non-glomeratous neoplasms, index of tumor aggressivity, 901(ab) increased accumulation
stress-induced myocardial ischemia, 933(ab) kinetic model
mapping of rate constants, 1001(ab) labeling of proteins, 982(ab) oxidative metabolism and primary gliomas, PET, 735(ab) potential ligand
neuro-ped studies, 706 radiation absorbed dose bladder wall, 899(ab) radioligand
synthesis and biodistribution, mice, 226 rapid parameter estimation techniques individual rate parameter comparison, dynamic PET, 940(ab)
single PET study
two sets of metabolic data, 733(ab) synthesis
effect of position during stress testing
dopamine, 936(ab) Fibrinogen
urinary metabolites iodine atoms, 958(ab) Filters
nonstationary nonlinear scintigraphic images, 927(ab) Fluorine-18 cyclohexyloxazole
fast maximum likelihood method region-of-interest values, emission tomography, 895(ab) opiate receptor ligand
PET, 936(ab) Fluorine-18 L-dopa
high yield synthesis, 417 resorptive fluorination, 1896 imaging of MPTP-induced change turnover and damage to striatal dopamine, 879(ab) regiospecific synthesis, 734(ab) routine synthesis
F-18 acetyl fluorohydrate, 1462 Fluorine-18 estradiol
synthesis of halogenated vinylcarbohydride and
vinylestradiol derivatives
cleavage of vinyl-tin bonds, 972(ab) Fluorine-18 Fluoride
reactor-produced purity determination, high pressure ion chromatography, 1047(ab) Fluorine-18 fluorodeoxyglucose
new tracer of glycoprotein metabolism, 983(ab) Fluorine-18 fluoroethylspiperone
preparation evaluation as D-2 receptor ligand, 982(ab) Fluorine-18 FFSNP
binding to dopamine receptors, 104(ab) Fluorine-18 methylestropiperidol
antipsychotic drug D-2 receptor schizophrenia, 880(ab) radiolysis, 982(ab) Fluorine-18 radioligand
no-carrier-added
syntheses and biodistribution, 906(ab) 16a-Fluoroestradiol-17β
synthesis
effects of diffusion limitation, 955(ab) 3'-2-(18F)-3-[(18F)-fluoroethyl]spiperone
dopamine receptor characterization, 879(ab) 5-Fluorouracil
radiopharmaceuticals
NMR and, 737(ab) Food and Drug Administration (FDA)
Congress takes no action on FDA fee, N1668 FDA approves In-111 oxyquinoline, N170 FDA approves 30 new drugs in 1985 including four diagnostic agents; Federal budget for FY 1986 to cut millions from FDA, NIH, and Medicare, N444 FDA orphan drug program ready to aid radiopharmaceutical investigations, N743 Nuclear medicine faces bright future when new diagnostic agents reach market, N1 (correction, misspelled radiopharmaceutical, N170) Senate hearings on FDA user fee, N450 early upset policy bill for export of drugs awaiting FDA approval, N1108 Fourier analysis
cardiac pacing Wolf-Parkinson-White syndrome, 993(ab)
Frost bite

length-based
pre-excitation syndrome, 1131
Frost bite
experimental
Tc-99m PYP study, 952(ab)

G

Gadolinium
GD-DISIDA
potential contrast agent, hepatobiliary system, 882(ab)
monoclonal antibodies
NMR and gamma camera tumor imaging, 829
NMR contract agents, 915(ab)

Gadolinium-153
development of instrument system
gamma camera, dual photon absorptiometry, 987(ab)
hepatobiliary imaging, 1044(ab)
scaled sources
dual-photon bone mineral scanners, 1067(ab)

Gallbladder
cholecystokinin cholescintigraphy
acalculous biliary disease, 882(ab)
fossa
increased hepatic activity, prognostic value during cholescintigraphy, 938(ab)
function
diabetes and, 357
morbidity, obesity, 882(ab)

Gallium
tumor scanning
ideal time, 1030(ab)
uptake
correlation with degree of malignancy, non-Hodgkin’s lymphoma, 1031(ab)

Gallium-67
AIDS patients may benefit more from wholebody scanning than from lung studies, N15 antibody
chelating agent effects, 1746
antibody labeled with coupling agent effects, 1042(ab)
arterial and venous thrombus, 1036(ab)
chest scans
Kaposi’s sarcoma and/or AIDS, 914(ab)
citrate
abscesses, 1883
citrate vs. In-111 monoclonal antibody melanoma detection, 922(ab)
cost/benefit of AIDS management
P. Carinii pneumonia, 914(ab)
differential uptake
tumors and inflammatory lesions, 1300 imaging
blastomyositis, 1015(ab)
imaging in heart transplants, 994(ab)
imaging in oat cell carcinoma, 1032(ab)
labeled monoclonal antibody human osteosarcoma, 1021(ab)
mechanism of accumulation tumors, 1215
role of radiography/scintigraphy/CT diagnosis and management of chronic osteomyelitis, 978(ab)
scintigraphy
amiodarone pulmonary toxicity, 993(ab)
Gardner’s syndrome, 1032(ab)
scintigraphy and MRI osteomyelitis, 978(ab)
suprastellar/thigh ratio rheumatoid arthritis and osteoarthritis, knees, 989(ab)

thoracic uptake
sarcoïdosis, 1550
uptake
enhancement by propranolol hydrochloride, sarcoma, mouse, 243
hepatic, enhancement by asialo-transferrin, 395
lung, asbestos exposure and, 538

Gallium-67 citrate
incidental uptake
lacrimal glands, sarcoïdosis diagnosis, 951(ab)
sцинтigraphy
parathyroid carcinoma visualized by, 63
Tc-99m HMDP sequential imaging painful prostate infection, 1413
Gallium-67 deferoxamine-dihydroxy starch
fibrinogen scintigraphy
location of vascular thrombs, 965(ab)

Gallium-68 EDTA
blood-brain barrier in dementia, 1074(ab)
routine pyrogen testing
limulus lysate technique for, 1798(ab)

Gallium-68 fluorosulphate
liver imaging
positron camera, 890(ab)

Gamma camera
SPECT system
poison noise for, 1070(ab)

Gamma camera comparison of spatial resolution
180° vs. 360° SPECT imaging, 1016(ab)
development of instrument system
dual photon absorptiometry, 987(ab) electronic collimation high energy single photons, 931(ab)
first pass radionuclide angiography compared to multicrystal camera, 911(ab)
gastric emptying in infants
gastroesophageal reflux disease, 904(ab)
image recording
variation in density, 128
I-123 iododehydradecanoic acid metabolic liver studies, 1533
iterative attenuation correction in SPECT attenuation coefficients, transmission measurements, 1004(ab)
magnetic fields up to 10 G performance changes, 1902
Monte Carlo simulations experimentally measured scatter fractions, 960(ab)
NEMA standards for scintillation cameras, N1518
new 3D technique, 917(ab)
physiological data by computer and, 1755
quality assurance images moiré interference, 820
scatter correction methods
SPECT, 884(ab)
screening
superior vena cava obstruction, 838

Gastrointestinal activity
In-111 leukocytes clinical significance, patients with fever, 1015(ab)

Gastrointestinal bleeding
detection by selective intraarterial Tc-99m sulfur colloid scintigraphy, 956(ab)
detection with Tc-99m RBC glucagon effects, 1941(ab)
imaging with Tc-99m red blood cells determination of bleeding rates, 956(ab)
sцинтigraphy
Tc-99m RBC, 491
scintigraphy pediatric, 1034(ab)

Gastroplasty
morbidity, obesity
gastric emptying studies in, 1686

Gated blood-pool studies
assessment of ventricular performance acute myocardial infarction, radionuclide angiography, 991(ab)
atrial and premature beats LV EF analyzed frame and list mode, 935(ab)
atrial fibrillation cycle length windowing, 935(ab)
cardiac response
ambulatory ventricular function monitor, 911(ab)
3D analysis, 918(ab)
coronary artery disease
diastolic function, effect of age, 990(ab)
labeling plasma proteins Tc-99m labeled agent, radionuclide ventriculography, 999(ab)
left ventricular volume determination
SPECT. 91(ab)
measurement of left ventricular function
ambulatory monitor. 91(ab)
VAST, validation and variability. 1002(ab)
preservation of rest/exercise systolic/diastolic
ventricular function
chronic alcoholics, 989(ab)
pressure-volume relationship
left and right ventricles, pacing-induced
myocardial ischemia. 934(ab)
regional phase mapping
gated nuclear angiography or tomography,
ventricular tachycardia. 992(ab)
temporal Wiener filtering
site of electrical activation. 1000(ab)

Gated heart studies
assessment of ventricular performance
acute myocardial infarction, radionuclide angiography,
991(ab)
congenital heart disease
cine magnetic resonance imaging. 985(ab)
dynamic arrhythmia flotation. 1347
gated radionuclide ventriculography. 990(ab)
oblique MRI
myocardial infarct evaluation. 986(ab)
pattern recognition classification
cardiac LV RWMA, radionuclide ventriculography,
927(ab)
superiority of factor analysis
regional wall motion abnormalities. 991(ab)

Gates method
measurement of GFR. 1373(le)

Gaucher's disease
scintigraphic findings. 1557

Generators
Os-191/Te-191m
evaluation, constant infusion mode. 916(ab)

Generators, isotope
preparation of Yt-90 labeled antibodies
patient use. 959(ab)
radioassay/radiation dosimetry. 1038(ab)

George Taplin Memorial Lecture
perfusion and receptor SPECT in the dementias. 855

Giant cell tumor
bone
radionuclide scanning. 329

Gloma
flurodeoxyglucose rate and oxidative
metabolism
measured by PET. 735(ab)

Glomerular filtration rate
comparison of measurement. 928(ab)
determination. 1645(le)
determination by Gates' method. 1644(le)
determination by single-plasma sampling technique
radioiodinated diatrizoate injection and, 45
gates method for measurement. 1373(le)
measurement
severe renal disease. 573(ab)
prediction in children
single sample method. 918(ab)
see also Kidney
Te-99m DTPA measurement
background correction for. 1070(ab)

Glucose metabolic rate
cerebral. PET measurements of. 1358
transport
brain. 1867
transport and phosphorylation
cerebellum. Alzheimer's disease. 955(ab)

Glucose metabolic rate
comparison with C-14 glucose and F-18
flurodeoxyglucose
double tracer quantitative digital
autoradiography. 956(ab)

Glucose metabolism
cerebral
normals, AIDS, and leukemia survivors. 945(ab)
variation of 2-FDG/glucose lumped constant
substrate and hormone concentrations. 966(ab)

l-Glutamate
N-13 t. valine comparison
sarcoma. 1030(ab)

Golter
intrathoracic
evaluation of upper mediastinal mass.
radiouclide thyroid scan. 887(ab)

Gold-195m
first pass studies
comparison with Kr-81m gated right
ventricular studies. 602

Graduate medical education
see Residency programs

Granulocytes
In-111
d- sulfur and antimony colloids. functional
differences. 1016(ab)
labeling
evaluation, In-111 chelated to three agents. 1014(ab)
migration
In-111-labeled, bronchiectasis. 950(ab)

Growth plate
angular deformity
scintigraphy. 1034(ab)

Gynecological tumors
potential utility of Indium-111 OC-125
antibody. 881(ab)

Haloperidol
radioiodinated analogue. 1055(ab)

Heart
SPECT imaging
fan beam collimator. design and clinical
utility. 810

trauma
PET, MRI, and XCT. 919(ab)

Health maintenance organizations (HMOs)
Commentary. Nuclear medicine in a PPO and
HMO era. N1516

Health Physics Society (HPS)
HPS membership votes on committed dose.
N328

H
diabetic treatment rejection
radioantibody detection. 996(ab)
diabetic
geradionuclide ventricular function parameters. 912(ab)
aortic insufficiency
NMRI. 985(ab)
assessment of coronary reserve
PET. compared to coronary arteriography.
943(ab)

beta-adrenergic receptors
C-11 CDP 12177, PET. 949(ab)

blood flow
high-resolution scintigraphy. 1586
boronic acid adducts of technetium oxime
complexes
myocardial imaging. 893(ab)

cardiac autonomic neuropathy
gastric emptying, diabetic patients. 1009(ab)

Cardiology meeting in Japan examines PET
applications in coronary artery disease;
Kyoto University PET Center pursues
routine clinical PET studies. N1383

congenital disease
cine MRI. 985(ab)
coronary and noncoronary artery disease
regional wall motion abnormalities by phase
analysis, radionuclide angiograms. 781
coronary arteriography and TI-201 scintigraphy
postexercise ST segment depression. 998(ab)
coronary occlusion
Re-82 kinetics after. 1456
detection of coronary artery disease
analysis of diastolic function. effect of age.
900(ab)
determining pressure-volume loops
clinical setting. 992(ab)
discette subaortic stenosis
TI-201. 1009(ab)
3-D surface mapping
functional PET images. 918(ab)
dynamic arrhythmia flotation
radionuclide imaging.
1347
dynamic PET studies
temporal information for spillover correction.
980(ab)

endomyocardial fibrosis
scintigraphic patterns. 990(ab)
exercise TI-201 scintigraphy
prognostic stratification of. angina. 954(ab)
fatty acid metabolism
myocardial. 1449
fatty acid uptake
radioiodinated. 521
first-pass radionuclide angiography
multiwire gamma camera. 911(ab)
free beta-adrenergic receptor density
quantitative assay. 949(ab)
gated radionuclide. ventriculography. 990(ab)
I-131-iodobenzylguanine-porphophonium acetate
and biological properties. 971(ab)
l-131 MIBG accumulation in
rat. 84

imaging of myocardial perfusion
Te-99m SQ 30217. 893(ab)
improvement in coronary flow reserve
coronary angioplasty. PET. 977(ab)
In-111 agents
SPECT system. 1073(ab)
In-111 monoclonal antibody
doxorubicin-induced cardiotoxicity. 994(ab)

H
diabetic treatment rejection
radioantibody detection. 996(ab)
diabetic
geradionuclide ventricular function parameters. 912(ab)
aortic insufficiency
NMRI. 985(ab)
assessment of coronary reserve
PET. compared to coronary arteriography.
943(ab)

beta-adrenergic receptors
C-11 CDP 12177, PET. 949(ab)

blood flow
high-resolution scintigraphy. 1586
boronic acid adducts of technetium oxime
complexes
myocardial imaging. 893(ab)

ischemia
regional distribution. Te-99m-hexakis-
aliphatic isonitriles. 994(ab)
Te-99m isonitriles. 8(ab)
ischemic myocardium
modified fatty acid analog. redistribution.
966(ab)

left to right shunts
factor analysis in evaluation of. 1442
left ventricular diastolic function
effect of gating modes. 935(ab)

left ventricular regurgitation
factor analysis and deconvolution,
angiography compared to invasive
techniques. 991(ab)
malposition
radionuclide angiography. adults. 484
modified oblique cardiac MRI
advantages. 1796(ab)

valvular vegetations detected by. 1796(ab)
Heart rate
multiple ventricular tachycardia
scintigraphic evaluation, 989(ab)
myocardial perfusion imaging agents
nondurable 99m-Tc(III) cations, 894(ab)
myocytes
Tc-99m uptake, 404
new Tc-99m myocardial agent
low plasma binding, fast blood clearance, 894(ab)
Oak Ridge National Laboratory incites active nuclear medicine research program: Heart imaging agents form core of ORNL nuclear medicine group, N155
pharmacology of Tc-99m-isonitriles, 7(ab)
positron camera
position-sensitive detectors, 90
preservation of ns/exercise systolic/diastolic ventricular function
chronic alcohols, 989(ab)
radiouclide angiography
high count rate first-pass, digital gamma camera, 198
regional phase mapping
gated nuclear angiography or tomography, ventricular tachycardia, 992(ab)
rejection of transplants
In-111 antimonyin Mah, detection, 910(ab)
right and left ventricular ejection fraction correlation, volume measurements, 991(ab)
right atrial time-activity curve analysis
comparison with Doppler echocardiography, tricuspid regurgitation, 92(ab)
right ventricular ejection fraction
improving the technique, children, 91(ab)
myocardial infarction, transfer function analysis, 968(ab)
right ventricular function
therapeutic response, chronic cardiac failure, 934(ab)
spectroscopy and echocardiography, 1635
significance of slow myocardial washout rate
Tl-201, 953(ab)
SPECT imaging of cardiac transplant rejection
In-111 antimonyin antibody, 910(ab)
Tl-201 myocardial imaging
during oral diprymidol-induced coronary vasodilation, 31
Tl-201 ischemia
coronary artery disease, significance of exertional angina, 998(ab)
transplants
Ga-67 imaging, 994(ab)
turnover of I-123
glucose-insulin influences on, 1044(ab)
uptake of Tc-99m TBI and Tl-201 transplants, 966(ab)
"upward creep"
Tl-201 stress-redistribution SPECT, 899(ab)
variation of 2-FDG/glucose lumped constant substrate and hormone concentrations. 966(ab)
Heart rate
peak exercise
normal Tl-201 myocardial clearance and, 26
wall thickness and chamber size
myocardium, 653
Hemangiona
hepatic cavernous
labeling of red blood cells, 1940(le)
Hemophilia
hepatic artery aneurysms
scintigraphic detection with Tc-99m RBC, 491
Hemophilia
chronic synovitis
intra-articular Yt-90 therapy, 987(ab)
Hemorrhage
occult
scintigraphic detection, anticoagulants and, 223
Heparin
Tc-99m red blood cell labeling and, 1202
Hepatic artery infusion pump
radioisotopic assessment, 1031(ab)
Hepatobiliary ducts
activity per unit volume
pitfall in predicting size, 869(le)
Hepatobiliary imaging
alteration of DISIDA kinetics as a function of time, 937(ab)
assessment of liver transplant function
decovolutional analysis, 1013(ab)
bile and blood flows
upper abdominal reconstructive surgery, 101(ab)
cholecytokinin cholecistography
acalculous biliary disease, 882(ab)
dynamic SPECT via time-shifting, 980(ab)
effect of endoscopic sphincterotomy, 937(ab)
excretory cholecistography and Tc-99m DISIDA, 938(ab)
gallbladder
morbid obesity, 882(ab)
gallbladder fossa
increased hepatic activity, prognostic value during cholecistography, 938(ab)
GD-DISIDA
potential contrast agent, 882(ab)
liver transplant function, 451
MRI contrast agents for, 1044(ab)
nonvisualization
sensitivity and positive predictive index, total biliary obstruction, 883(ab)
pitfalls in evaluation
neontal cholestasis, Tc-99m, 931(ab)
radiolabeled triglyceride, 1046(ab)
rim sign
cholecyctis and, 353
Ru-97-DISIDA, 1072(ab)
Tc-99m scintigraphy
efficacy and cost-effectiveness, 883(ab)
uptake of Tc-99m DISIDA, 938(ab)
Hepatocellular carcinoma
immunoscintigraphy
double isotope emission tomography, 1022(ab)
necessity of radionuclide liver scan, 1012(ab)
Hepatocellular diseases
diffuse
SPECT diagnosis, 616
Hepatoma tumor
accumulation of tumor-seeking agents, 1049(ab)
Hexahaloheptenate reagents
synthesis of Tc-99m complexes, 1049(ab)
High-density avalanche chamber installation, 1073(ab)
High-performance hydroxyapatite chromatography
purification of monoclonal antibody fragments, 1043(ab)
HIPDM
cerebral imaging
dexamethasone enhancement of, 1627
Hipparus
commercial
radiochemical purity and in vitro stability, 850
History of nuclear medicine
see Nuclear medicine history
Huntington's disease
brain metabolism
99mTc-99mGF, 920(ab)
caudate hypometabolism, 920(ab)
PET, 1074(ab)
Hydrocephalus
cerebral spinal fluid shunt assessment, 1025(ab)
Hypercaldemia
familial hypercalciuric renal tubular function in, 580(ab)
Hyperparathyroidism
bone scan
metastatic calcification of thyroid gland, 373
evaluation of bone mineral loss
single and dual absorptiometry, 886(ab)
in renal osteodystrophy
subtraction scanning in, 580(ab)
secondary evaluation
parathyroid imaging methods in, 580(ab)
Hyperplasia
nodular regenerative
liver, scintigraphy, 563(le)
Hypertension
captopril challenge
radionuclide assessment, 576(ab)
curable
captopril as a predictor of, renal transplant recipients, 576(ab)
dual tracer autoradiographic study
fatty acid analogs, 1178
intrahepatic
isotope cisternography, 471
2 kidney and 1 kidney Goldblatt
captopril challenge, Tc-99m DTPA, 961(ab)
renal artery stenosis
captopril, enhanced renal scintigraphy, 962(ab)
renal function changes in
convertingenzyme inhibition and nitisinamide effects, 575(ab)
renovascular
captopril challenge, 962(ab)
captopril renography, 961(ab)
captopril renography in, 575(ab)
Rb-82 PET evaluation of, 1054(ab)
total and split renal function in, 1054(ab)
Hyperthermia
In-111 macrophage distribution, 1015(ab)
Hyperthyroidism
toxic inrathoracic goiter, 1423
Hypertrophy
benign prostatic
impotence and, Xe-133 washout, 1036(ab)
Hypoperfusion
global and segmental
captopril, renal scintigraphy after, 576(ab)
Hypothyroidism
Hashimoto's thyroiditis and iodine uptake, elderly women, 909(ab)
Hypoxia
evaluation and identification
animal model, 969(ab)
IAEA
see International Atomic Energy Agency
I
Iodinated acid
lesioning
Alzheimer's disease, 913(ab)
Image analysis
nonstationary nonlinear filters
scintigraphic images, 927(ab)
Image processing
automated comparison, 1337
1970
The Journal of Nuclear Medicine
Indium-111 troponol

FDA approves In-111 oxyquinoline, N170

Indium-111 troponol
In-111-oxine-labeled leukocytes
comparison, three techniques. 1014(ab)
kineetics of eosinophils
human body, 1014(ab)

Indium-111 vesicles
human tumor imaging, 971(ab)

Indium-111 white blood cells
comparison of granulocytes and mixed
leukocytes, 964(ab)
evaluation of granulocyte labeling, 1014(ab)

Te-99m skeletal scintigraphy
infected total hip prosthesis, 977(ab)
three-phase bone scintigraphy and Ga-67
osteomyelitis, 915(ab)

Inflammatory lesions
differential uptake
Ga-67-labeled liposomes, 1300

Instrumentation
Commentary: Toward a “win-win” relationship, N586
Nuclear medicine community explores
problems of computer/equipment market:
SNM Computer Council considers
formulating software guidelines, N585

Interferon
mRNA-labeled tumor necrosis factor
potential for tumor imaging, 970(ab)

International Atomic Energy Agency (IAEA)
IAEA plays major role in promoting nuclear
medicine in developing countries, N9
quality of nuclear medicine imaging
developing countries, 1019(ab)

International Radiation Physics Society (IRPS)
International Radiation Physics Society
founded, N1108

Intrathoracic goiter
toxic
hyperthyroidism caused by, 1423

Inverse Monte Carlo
unified reconstruction algorithm for ECT, 1577

Iodine-123
digital restoration of images
optimized Metz filters, 1327
evaluation of fatty acid uptake
myocardial, 521
glucose-insulin influence on, 1044(ab)
hypothyroidism and Hashimoto’s thyroiditis
iodine uptake, elderly women, 909(ab)
impact of radiocontaminants in, 428
myocardial blood flow, 1048(ab)
radiouclide contaminants in, 1801(ab)

Iodine-123-4-amino-3-iodobenzylguanidine
adrenal uptake, 1138

Iodine-123 amphetamine
blood flow
cerebrovascular disease, 1029(ab)
133-Xe SPECT and PET
chronic cerebral infarcts, 888(ab)

Iodine-123 antibodies
SPECT imaging
comparison of collimators, 1467

Iodine-123 estradiol
synthesis of halogenated vinylcarboxylate and
vinylestradiol derivatives
cleavage of vinyl-tin bonds, 972(ab)

Iodine-123 Fab fragments
colorectal carcinoma
biokinetincs, 1019(ab)

Iodine-123 fatty acid
compared to TI-201 uptake
myocardial ischemia, reperfusion, 997(ab)
coronary artery disease
metabolic studies, 891(ab)
necrotic myocardium
modified fatty acid analog, redistribution,
966(ab)
myocardial imaging
invasive heart disease, 891(ab)

Iodine-123 HIPDM
broad spectrum flow
labeled amine perfusion agent uptake and,
1028(ab)
comparison with Te-99m-d,1-HM-PAO
regional brain perfusion, 1819
kinetic model
local cerebral blood flow tracer, 941(ab)
pancreas imaging
SPECT, 1013(ab)

Iodine-123 hipuran accumulation
renal transplants, 579(ab)
evaluation of renal function
reflux uropathy, 582(ab)
gamma camera renography
ischemic injury
renal allografts, 579(ab)
quantitative evaluation, normal children, 117

Iodine-123 HFA
kinetics
normal heart, 1449

Iodine-123 IMP
assessment
mild/moderate and severe Alzheimer’s
disease, 889(ab)
cerebral dynamics, 178
colonic
portasystemic shunt fraction, 1321
correlative studies
brain, 1029(ab)
3D display
emission tomographic data from brain,
917(ab)
demonstration of metastatic melanoma, 971(ab)
itobenic acid lesioning, 913(ab)
measurement of cerebral blood flow
ischemia, 1028(ab)
no-carrier-added synthesis via organonobranes,
1045(ab)
partial complex seizures or hallucinations,
1029(ab)
perfusion and receptor SPECT in the dementia
George Taplin Memorial Lecture, 855
study of dementia, 761

Iodine-123 iodocyanopindolol
biodistribution and competitive binding,
971(ab)

Iodine-123 lodoheptadecanoic acid
metabolic liver studies, 1533

Iodine-123 IP
cardiac
reversible stress-induced inhibition of,
1068(ab)

Iodine-123 MIBG
adrenergic imaging, 1138
clinical contribution of scans in neuroblastoma,
947(ab)
index of neuron activity
myocardial infarction, 949(ab)

Iodine-123 monoclonal antibodies
anticarcinoembryonic fragments
ECT detection of colorectal cancer, 880(ab)

Iodine-124
thyroid tomographic imaging, 909(ab)

Iodine-125
high specific activity synthesis, 1165
monoclonal antibodies, 959(ab)

Iodine-125 antibodies
catalysin
liver, 939(ab)

Iodine-125 derivatives
epitctic and AMSA
synthesis and melanoma avidities, 1076(ab)

Iodine-125 etomide
analogs
radiolabeled, 1076(ab)

Iodine-125 fibronecten
platelet and fibrogen deposition
vitamin E on graft thrombosis, 947(ab)

Iodine-125 HEAT
labeling
alpha-1 adrenergic receptors, 969(ab)

Iodine-125 HIPDM
pulmonary accumulation
lung model, 1038(ab)

Iodine-125 IMP
no-carrier-added
preparation and tissue distribution, 940(ab)

Iodine-125 2’-iodoisopropenol
SPECT studies of dopamine receptor, 972(ab)

Iodine-125 iodovinylestradiol
tissue distribution of derivatives
estrogen receptor, 939(ab)

Iodine-125 lathalame
glomerular filtration rate measurements
severe renal disease, 573, 928(ab)

Iodine-125 LPM
platelet membrane functions, 1046(ab)

Iodine-125 MIBG
analogs
catecholamine stores, central, 1076(ab)

Iodine-125 monoclonal antibodies
diagnosis and radiotherapy
one-vial method, 1890

Iodine-125 QNB
ibotenic acid lesioning, 913(ab)
radiodiiodination of
no-carrier-added concentration, 1045(ab)

Iodine-131
comparison of radioimmunotherapy and 4 MV
external beam radiotherapy
tumor xenografts, 902(ab)
diagnostic dose for imaging
thyroid cancer, 1764

fetal dosimetry
first month of pregnancy, 1007(ab)

In-111 and
labeled to T-101, cutaneous T-cell lymphoma,
903(ab)
metastases survey
sporuous thyroid cancer metastasis, 634
parathyroid localization
radiodiiodinated toluidine blue, Te-99m-
thyroid suppression scintigraphy, 963(ab)
post-therapy retention
external monitoring versus urine assay,
1071(ab)

radioactive uptake
breasts, 149, 150(e)
rational dose therapy
metastatic well-differentiated thyroid
carcinoma, 1519

staging of thyroid cancer, 886(ab)
thyroid cancer
absorbed dose, 1207
metastatic to the brain cerebral edema
following, 637
quantitative SPECT therapy in, 737(ab)
Iodine-131 albumin
dual tracer technique
lung vascular permeability, 979(ab)
Iodine-131 anti-CEA
second-clearance
radioimmunodetection of cancer, 897(ab)
Iodine-131 BDP3
palliative treatment
bone metastases, 1255
Iodine-131 fatty acid
regional myocardial uptake and blood flow
autoradiography, 933(ab)
Iodine-131 HIPDM
dual-tracer studies
C-14 tryptophan, pancreatic diseases, 957(ab)
pulmonary accumulation, 1076(ab)
Iodine-131 hippuran
detection of glomerular lesions, 502
extracorporeal shock wave lithotripsy
treatment of kidney stone, 928(ab)
pure tubular renogram curves
factor analysis, 1006(ab)
renal function
renovascular hypertension, 1054(ab)
Iodine-131-iodobenzyltriethylphosphonium acetate
synthesis and biological properties, 971(ab)
Iodine-131-6-iodocholest-5-en-3β-ol
high specific activity synthesis, 1165
Iodine-131-6-iodomethylcholesterol
adrenal scintigraphy
clinically silent adrenal mass lesion, 908(ab)
Iodine-131 MIBG
carcinoid tumors, 1691
carcinoid tumors and apudomas, 1221(le)
clinical contribution of scans in neuroblastoma, 947(ab)
correction of I-131 uptake vs. time curves, 898(ab)
CT imaging
diagnosis of pheochromocytoma, 929(ab)
CT/MRI correlation
detection of pheochromocytoma, 1010(ab)
diagnosis of neuroblastoma, 931(ab)
dosimetry in metabolic radiotherapy
neuroblastoma, pheochromocytoma, 1008(ab)
imaging of fresh venous thrombi, 941(ab)
imaging in neuroblastoma, 947(ab)
imaging of muscular thyroid carcinoma, 1150
impaired myocardial retention
chronic volume-overload heart failure, 1068(ab)
locating pheochromocytoma, 1222(le)
medullary cell uptake
carcinoma, thyroid, 1071(ab)
neuroendocrine tumor avidity
significance in MIBG therapy, 948(ab)
neuroblastoma, 1800(ab)
scanning
solid tumors, children, 620
small cell carcinoma
lung, 1785(e)
thyroid medullary carcinoma, 1858
uptake
neuroblastoma, 726(le)
Iodine-131 monoclonal antibodies
colon cancer
prospective study of recurrence, 1023(ab)
comparison of route of administration
colorectal cancer, 902(ab)
diagnosis and radiotherapy
one vial method, 1890
radioimmunotherapy
colon carcinoma xenografts, 1019(ab)
Iodine-131 OH
comparison with Tc-99m MAG3
normal subjects and patients, 962(ab)
renal transfer function, 574(ab)
replacement with Tc-99m MAG3, 571(ab)
Tc-99m MAG comparison
renal imaging, 795
Iodine-131 peanut lectin
tubular renal receptor imaging, 668
Iodine-131 pindolol
gamma scintigraphy and
characterization of beta-adrenoceptors, 660
Iodine-131 sodium iodide
determination of tracer dose
metastatic thyroid cancer, small-source photon, 886(ab)
Iodine-131 tyramine cellbiose-LDL
compared to Tc-99m LDL
kinetics and biodistribution, 995(ab)
Iodoxamyl
compared with isopropylodobenzamine
TI-201 diethyldithiocarbamate as tracer, CBF, 913(ab)
Iodocarboxylates
brain imaging agents, 1054(ab)
15-p-(I-131)-iodophenyl-β-methylpentadecanoic acid
dual tracer autoradiographic study of
hypertension, 1178
Iodophenylpentadecanoic acid (IPPDA)
compared to new iodinated phenyl fatty acids
imaging myocardial metabolism, 939(ab)
Iodothioaurate
localizing agent of melanoma, 1157
15-p-(I-123)-phenyl pentadecanoic acid
regional myocardial extraction
compared with TI-201, 934(ab)
Iron-52-manganese-52m generator system
development and application, 732(ab)
Ischemia
cerebral
misonidazole uptake in, 1026(ab)
heart disease
comparison of three Tc-99m inionitriles, 8(ab)
three-phase bone scans, 1798(ab)
Isopropylodobenzamine
compared with iodooxamyl
TI-201 diethyldithiocarbamate as tracer, CBF, 913(ab)
Isotopes, stable
demand for isotopes sought by Oak Ridge,
N760
supply of stable isotopes from Oak Ridge affects
radiopharmaceutical production; Budget cuts limit operation of calutrons, N166
Jaundice
biliray scintigraphy
Tc-99m BIDA, 1407
Joint imaging
Tc-99m pyrophosphate
experimental hemarthrosis, 246
Jülich, Nuclear Research Center
Commentary: A one-year sabbatical in Jülich,
N1666
Medical advances surface from “whirlpool” at
the Nuclear Research Center Jülich;
Institutes of Medicine and Radiochemistry
join forces in scientific progress, N1803
K
Kidney
acute pyelonephritis in children
MRI, 985(ab)
captopril
diagnosis, renovascular hypertension,
renography, 961(ab)
enhanced renal scintigraphy, renal artery
stenosis, 962(ab)
renovascular hypertension, 962(ab)
characterization of Tc-99m MAG3, 939(ab)
cisplatin
tubular effects of, 571(ab)
clearance and extraction
Tc-99m MAG, and IOH comparison, 572(ab)
comparison of Tc-99m MAG3 and OIH
normal subjects and patients, 962(ab)
converting enzyme inhibition and nitroprusside
effects
hypertension, 575(ab)
dialysis treatment
In-111 leukocytes in, 579(ab)
drainage
conventional renogram effects, 573(ab)
effect of exercise position during stress testing
cardiac and pulmonary thallium kinetics, coronary artery disease, 788
effect of extracorporeal shock waves, 929(ab), 929(ab)
extracorporeal shock wave lithotripsy
treatment of kidney stone, I-131 hippuran, 928(ab)
failure
digoxin-like substance in, 1418
function
renovascular hypertension, 1054(ab)
uncontrolled variables in measurement, 1644(le)
function and scanning
DMSA scan, 582(ab)
function changes
angiotsin-converting enzyme and, hypertension, 1053(ab)
glomerular filtration rate
determination of, 1645(le)
Gates' method, 1644(le)
severe renal disease, 928(ab)
glomerular lesions
detection, radioactive agent comparison, 502, 513
In-111 lysosyme
metabolism of low-molecular-weight proteins, 962(ab)
interstitial function, importance of, 573(ab)
ischemia
P-31 MRS, 578(ab)
nephrofibroma
Tc-99m DTPA, 143(le)
osteodystrophy
hyperparathyroidism in, 580(ab)
noninvasive method of assessment, 580(ab)
subperiosteal bone formation in,
radiophosphate disclosure, 1572
physiology
spectroscopy of lithium isotopes, 733(ab)
plasma clearance
synthesis of continuous infusion, 1611
plasma flow
atrial natriuretic factor effects, 571(ab)
polycystic disease
In-111 leukocytes, 1376(le)
pure tubular renogram curves
factor analysis, I-131 hippuran, 1000(ab)
Kidney transplants

- Radiation absorbed dose: I-131 OIH, Tc-99m MAG3, 98(ab)
- Renal blood flow: PET with RI-82, 941(ab)
- Renal cortical infarction: Tc-DMPS scintigraphy, 918(ab)
- Renal volume estimation
- SPECT, phantom study validation, 1006(ab)
- RI-82 dynamics in, 105(ab)
- Single sample method
- Prediction of GFR in children, 918(ab)
- SPECT imaging with Tc-99m DMSA evaluation of children with reflex, 919(ab)
- Spleno-renal anastomosis: Splenic size in hepatosplenic schistosomiasis, 1013(ab)
- Tc-99m DMSA failure to visualize with, 377
- Tc-99m DTPA quality control, 560
- Tc-99m MAG3 evaluation as a hippuran replacement, 111
- Transplant
- Captopril as predictor of hypertension, 576(ab)
- Evaluation with Tc-99m DTPA, factor analysis in, 105(ab)
- In-111 oxine platelet scan, 578(ab)
- 1-123 accumulation, azathioprine and cyclosporin A therapy, 579(ab)
- Nephrotoxicity of cyclosporine A, 578(ab)
- Radiouclide ventriculography in management of, 579(ab)
- Viability assessment, P-31 MRS, 577(ab)
- Transplants
- Evaluation of tubular necrosis, factor analysis, 105(ab)
- Tubular function
- Familial hypocalciuric hypercalcemia, 580(ab)
- Triamide mercaptide complexes as agents, 105(ab)
- Urterocoeles and duplex renal systems
- Radiouclide scanning, 919(ab)
- Vascular transit time
- Tc-99m compounds, 1006(ab)

Kidney transplants

- Accurate diagnosis of rejection
  - In-111 platelet imaging, post-op cyclosporin therapy, 984(ab)
- Acute rejection
  - Cortical perfusion index, 1697
  - In-111 platelet scintigraphy, 1266
  - Donor specific transfusion rejection, 984(ab)
  - In-111 platelet imaging
  - Cyclosporin A, 984(ab)
  - In-111 platelets
  - Directed therapy, cyclosporin renal arteriopathy, 964(ab)
  - In-111 platelet scintigraphy, 983(ab)
- Patterns of rejection
  - Cyclosporin toxicity, 98(ab)
- Radiation absorbed dose profiles, 980(ab)

Kidney tubules

- Receptor imaging
  - L-131 peanut lectin, 668

Kinetics

- Blood platelet stimulation, 965(ab)
- Deoxyglucose-6-phosphate dephosphorylation effects of diffusion limitation, 955(ab)
- Dynamic PET
- Comparison of rapid parameter estimation and individual parameters, 940(ab)
- Eosinophils
  - Human body, 1014(ab)
- FDG
  - Mapping of rate constants, 1001(ab)
- 1-123 HEDPM
  - Local cerebral blood flow tracer, 941(ab)
- IQNB and the muscarinic ACh-receptor system brain, 937(ab)
  - Local cerebral blood flow
  - Examination of assumptions, PET, 1003(ab)
- N-13 ammmonia
  - Compartment analysis, myocardium, 940(ab)
  - PET static and dynamic protocols
  - Muscarinic cholinergic receptor binding, 936(ab)
  - Tracer
  - Stochastic approach, 981(ab)
  - Variability of T1-201 half-life
  - Rest to exercise, 997(ab)
- Krypton-79m ventilation studies
  - Lung, 1436
- Krypton-81m gated right ventricular studies
  - Comparison with Au-195m, 602
  - Lung scintigraphy, 361
  - Steady-state method
  - Right ventricular ejection fraction, 593
- Kyoto University PET Center
  - Cardiology meeting in Japan examines PET applications in coronary artery disease
  - Kyoto University PET Center pursues routine clinical PET studies, N1383

L

Lacrimal glands

- Incidental Ga-67 citrate uptake
  - Sarcoidosis diagnosis, 951(ab)

Left ventricular vertical orientation

- Planar myocardial perfusion images and, 694

Leg muscle

- Perfusion study
  - SPECT, 1035(ab)

Lesch-Nyhan syndrome

- Dopamine receptors in PET assessment, 1027(ab)

Leukemia

- Childhood survivors, cerebral glucose metabolism, 945(ab)

Liability

- Cancer screening to study fallout effects, N1390
- Computer program for epidemiologic tables, N1390
- National Council discusses licensure and future of allied health care; SNM Technologist Section offers liability insurance program, N1385
- U. S. Supreme Court rejects Mallinckrodt liability case, 1108

Licensing

- NRC reports on misadministrations and unannounced safety inspections, N1102

Liposomes

- Ga-67-labeled tumors and inflammatory lesions, 1300
- Tc-99m-labeled sites of fungal infection, use in amphotericin B therapy, 1016(ab)

Lithium

- Effect on dopamine receptor binding
  - C-11-3-N-methylpiperone, brain, 880(ab)

Lithium isotopes

- Spectroscopy of renal physiology, 733(ab)

Liver

- Angiosarcoma
  - Red blood cell scintigraphy, 1861
  - Assessment of preservation
  - NMR, 1071(ab)
- Biliary nonvisualization
  - Sensitivity and positive predictive index, total biliary obstruction, 883(ab)
  - Blood flow and reticuloendothelial function
  - Progressive cirrhosis effects, 1751
  - Catabolism
  - In-111 and I-125 antibodies, 939(ab)
  - Cavernous hemangioma
  - Labeling of red blood cells, 1940(ab)
  - Cirrhosis
  - Detection of gastrointestinal bleeding site, 435(ab)
  - Differentiation by Tc-99m IDA scintigraphy
    - Primary biliary cirrhosis, primary sclerosing cirrhosis, 1012(ab)
- Disease
  - Evaluation, SPECT vs. CAT, 924(ab)
  - Physiological manifestation, Tc-99m-IDA
  - Deconvolution analysis, 937(ab)
  - Ga-68 colloid tomographic imaging
    - Position camera, 890(ab)
- Ga-67 uptake
  - Enhancement by asialo-transferrin, 395
- Hemangiomatous
  - Contribution of SPECT imaging, 925(ab)
  - MRI and blood pool scanning, 924(ab)
  - Hepatic artery and portal vein blood flow
  - Quantitative measurement, deconvolutional analysis, 957(ab)
- Hepatocellular disease
  - Measurement of spleen/liver ratios, 1012(ab)
  - Imaging
    - SPECT, iterative attenuation correction algorithm, 701
    - Imaging agent
      - Radiolabeled triglyceride, 1046(ab)
  - In-111 chelated by DTPA-antibody, 943(ab)
  - Increased activity during cholescintigraphy
  - Prognostic value, adjacent to gallbladder fossa, 938(ab)
- Measurement of regional blood flow
  - Inhalation of Xe-133, 1012(ab)
- Metabolic studies
  - 11-C-[123]iodoheptadecanoic acid, 1533
  - MRI contrast agents for gadolinium-labeled, 1044(ab)
  - Necessity of radiouclide scan
  - Hepatocellular carcinoma, 1012(ab)
  - Nodal regenerative hyperplasia
  - Hepatic scintigraphy, 563(ab)
  - Oral administration of Tc-201
    - Assessment of portosystemic circulation, 957(ab)
- Size estimation
  - Patient positioning effects, 1632
- SPECT imaging, 1001(ab)
  - Spleno-renal anastomosis
    - Splenic size in hepatosplenic schistosomiasis, 1013(ab)
  - Tc-NGA functional imaging
    - Receptor-binding radiotracers, 924(ab)
  - Transplant function
    - Deconvolutional analysis, 1013(ab)
    - Sцинтиграфическая оценка, 451
    - Transplant function and structure
    - HIDA scanning, 925(ab)

Liver transplant

- Accurate demonstration of hepatic infection in, 1428
- Low-level waste
Lymph nodes
Te-99m MDP uptake
bone scans, 98(ab)
Lymphocytes
radioaggregated rejections, 896(ab)
Lymphoma
Cutaneous T-cell
biodistribution, I-131 and In-111 labeled to T01, 90(ab)
Non-Hodgkin's
gallium uptake and degree of malignancy, 103(ab)
Lymphoscintigraphy
Axillary
breast carcinoma patients, 1116
In-111 antitumor monoclonal
radioimmunoimaging, 1020(ab)
lymphedema, 1125
prostate
Te-99m SbSC, 1034(ab)

M
MAG3: see Mercaptoproctlyglycylglycylglycine
Mallinckrodt
U. S. Supreme Court rejects Mallinckrodt
liability case, N1108
Medical internal radiation dose (MIRD)
Free software available to calculate MIRD,
N1242
SNM publishes books on SPECT and MIRD:
New primes cover fundamental concepts
and methodology, N756
Melanoma
Comparison of two In-111 monoclonal
antibodies, 1020(ab)
detection
Ga-67 citrate vs. In-111 monoclonal
antibody, 922(ab)
GD2 specific I-131 labeled monoclonal
antibodies, 881(ab)
imaging with Fab and TI-201 chloride, 1022(ab)
immunoreactivity of Mab 96.5
production of inactive variants, 958(ab)
In-111 antitumor monoclonal
radioimmunoimaging, 1020(ab)
In-111 lymphocytes
Expansion with interleukin-2, 970(ab)
iodothiouracil as a localizing agent, 1157
melanotic and amelanotic B16
tumor-seeking agents in, 1045(ab)
metastatic
detection, In-111 DTPA antibody, 1019(ab)
monoclonal antibodies
immunoreactivity assay, 824
Mercaptoproctlyglycylglycylglycine
Te-99m
as a hippocampal replacement, 111
Metadobenzylguanidine
I-131
accumulation in heart, rat, 84
I-131-labeled
metabolism in metastatic
pneumocytes, 37
Kit-form analog of, 256
Metastatic calcification
Thyroid gland
Primary hyperparathyroidism, 373
α-Methyl-L-tryptophan
Dual tracer autoradiographic study of
hypertension, 1178
H-3-N-Methylpiperone
Binding alteration
Monoclonal antibodies
Serotonin-2 receptors, serotonin reuptake,
936(ab)
[11C]N-Methylpiperdidol
dopamine receptors
Improved detection of, 1878
α-Methyl-L-tryptophan
No-carrier-added
synthesis, 1047(ab)
Microdosimetry
Medical advances from "whirlpool" at
the Nuclear Research Center Jülich;
Institutes of Medicine and Radiochemistry
join forces in scientific progress, N1803
UK's Medical Research Council examines
radiopharmaceutical microdosimetry,
N1815
Microsurgery
lymphedema
lymphoscintigraphy and, 1125
Misadministration
NRC reports on misadministrations and
unannounced safety inspections, N1102
Moderator band hypertrophy
Pulmonary sarcoidosis, 725(ab)
Moïse interference
gamma camera quality assurance images, 820
Monoxide oxidase-B
Turnover in brain
C-11 t-deprenyl, 982(ab)
Monoclonal antibodies
Anti-CEA
colorectal carcinoma, 1796(ab)
anti-human parathyroid
evaluation, 958(ab)
anti-melanoma
immunoreactivity assay, 824
anti-mouse responses
therapy in human patients, 942(ab)
anti-murine
immunoscintigraphy or therapy, radiolabeled
Mab, 1022(ab)
anti-tumor
detection of labeled, 1041(ab)
Bi-212 labeled
radioimmunotherapy, 1040(ab)
bismuth-212-labeled anti-TAC
T-cell leukemia radioimmunotherapy,
897(ab)
CEA
cancer radioimmunodetection, 897(ab)
cell binding and accumulation
tumor xenografts, 1020(ab)
comparison
pulmonary embolism, clot detection, 923(ab)
Cu-67-labeled
design of, 1041(ab)
cutaneous T-cell lymphoma
radioimmunodetection, 903(ab)
effect of circulating anti-murine antibody
injected radiolabeled monoclonal antibody,
922(ab)
Experimental thrombi, 1315
Experimental tumor localization, 1293
Factors affecting uptake
human xenografts, 922(ab)
Ga-67 citrate vs. In-111 monoclonal antibody
melanoma detection, 922(ab)
Ga-67-labeled
NMRI and gamma camera tumor imaging,
829
GD2 specific I-131
Melanoma, osteogenic sarcoma and
neuroblastoma, 881(ab)
HT 29-15
Monoclonal antibodies HMFG-1

immunocitography, colon metastases, 1023(ab)
lgm.
radioimmunodetection, colon and gastric cancer xenografts, 1022(ab)
1-131 LYM-1
radioimmunotherapy, B-cell lymphoma, 903(ab)
imaging metastatic tumors in brain, 1028(ab)
immunoreactivity of Mab 96.5 against 899(ab)
melanoma
production of inactive variants, 958(ab)
In-111
neutrophils, evaluation, 947(ab)
in-111 antimelanoma
radioimmunoimaging, 1020(ab)
Indium-labeled platelets, 975(ab)
in-111-labeled
attempts to saturate hepatic clearance mechanism, 921(ab)
labeling and characterization of an antiplatelet Mab
potential usefulness for general antibody labeling, 958(ab)
labeling with In-113m, 1015(ab)
multicompartmental analysis of kinetics cancer patients, 1243
mutant anti-ARS
Oncology emphasizes strength of nuclear medicine in tissue characterization:
European Nuclear Medicine Congress 1986 scientific highlights, N1653
pharmaceuticals and imaging, 1023(ab)
PAX-276
In-111, diagnosis of metastatic prostate cancer, 1021(ab)
polyethylene-radiolabeled, 1043(ab)
purification
(HPHT), 1043(ab)
radioactivity detection of cardiac allograft rejection, 998(ab)
radioidinatation, 959(ab)
radiolabeled scintigrams
simple means of display, 545
radioiodolizing
concaved epitopes, carinoembryonic antigen. 1016(ab)
reactivity against osteosarcoma, 921(ab)
Report published on immunotherapy market, N450
Richard Wahl receives Tctalman Award for monoclonal antibody research, N1388
Tc-99m metallothionein
imaging xenografts, 191(ab)
tumor localization, 1015(ab)
tumor xenografts
radioimmunoimaging of, 1739
Two biopharmaceuticals approved in Japan, N450
uptake
tumor size effects, 422, 1789(le)
urinary metabolites
fibrinogen, iodine atoms, 958(ab)
use of alpha emitter
therapy against adenocarcinoma, 898(ab)
Monoclonal antibodies HMFG-1
parenteral administration, 1801(ab)
Monoclonal antibodies T-101
immunoreactivity changes in DTPA conjugation, 1040(ab)
MPTP
C-11
tracer for Parkinson's disease, 1600
MRI: see Nuclear magnetic resonance
diprydiamole thallium images, 944(ab)
effect of eating
Tl-201 redistribution postischemia, 953(ab)
effect of Thallium images
distribution abnormalities, 997(ab)
extravasation of IPPA
compared with Tl-201 uptake, 934(ab)
first pass ejection fraction
perfusion with Technetium-99m isonitrile, 878(ab)
glucose metabolism
postischemic myocardium, 890(ab)
imaging
I-123 phenylpentadecanoic acid, 891(ab)
imaging with Tc-99m T-BIN, 994(ab)
measurement of left ventricular function
VEST, validation and variability, 1002(ab)
modified fatty acid analog
distribution, 966(ab)
pacing-induced
pressure-volume relationship, left and right ventricles, 934(ab)
regional glucose metabolism
coronary anatomy, 967(ab)
reperfusion and
I-123 fatty acid compared to Tl-201 uptake, 99(ab)
severity
chronic ischemic heart disease, 989(ab)
severely depressed left ventricle
rest-redistribution Tl-201, improvement after revascularization, 933(ab)
stress-induced
increased fluorodeoxyglucose accumulation, 933(ab)
Tc-99m stannous pyrophosphate
serum MB-creatinine kinase, myocardial infarction, 994(ab)
Tl-201 clearance
peak exercise heart rate effects on, 26
Tl-201 kinetics and
rabbit, 66
transaxial SPECT Tl-201 perfusion imaging, 146(e)
Myocarditis
monoclonal In-111 antimyosin antibody imaging
versus right ventricular biopsy, diagnosis, 910(ab)
Myocardium
beta-adrenoreceptors
characterization with I-131 pindolol, 660
blood flow
I-123, 1048(ab)
flow measurement
H216O, dynamic PET, 976(ab)
chronic volume overload failure
I-131 MIBG, 1068(ab)
collateralized
coronary steal, noninvasive PET, 977(ab)
compartment analysis
N-13 ammonia kinetics, 940(ab)
contusion
TI-201 SPECT imaging, 998(ab)
definition of normal limits
stress TI-201 myocardial rotational tomography, 899(ab)
denervated
scintigraphic detection, 949(ab)
distribution of Tc-99m
reperfusion and hyperemia effects, 1172
doxorubicin-induced cardiotoxicity
In-111 antimyosin antibody, 994(ab)
dual-tracer autoradiographic study


**Subject Index • 1986**

**Nuclear medicine**

- I-131 MIBG, detection of pheochromocytoma, 1010(ab)
- detection of aortic insufficiency, 985(ab)
- early friends of, 437(le)
- gamma camera tumor imaging and Gadolinium-labeled monoclonal antibodies, 829
- GD-DISIDA potential contrast agent, hepatobiliary system, 882(ab)
- high-field thermal effects clinical experience, 1008(ab)
- imaging bone pathology, 207
- pulse sequence parameters for optimal tissue contrast, simulation procedure, 281
- importance of surface coil geometry, 1017(ab)
- liver preservation assessment, 1071(ab)
- marrow involvement lymphoma, 964(ab)
- MRI evaluation of anatomy 1.5T and 0.6T field strength, 985(ab)
- normal brain aging dementia, 969(ab)
- oblique MRI myocardial infarction evaluation, 986(ab)
- PET comparison cerebrovascular disease, 1026(ab)
- ProPAC issues report on the NMR reimbursement, N450
- prostate imaging, 948(ab)
- pyelonephritis children, 577(ab)
- radiopharmaceuticals of 5-Fu and, 737(ab)
- renal FLASH, 577(ab)
- renal function after shock wave lithotripsy, 577(ab)
- renal ischemia, 578(ab)
- renal viability assessment transplant model, 577(ab)
- scintigraphic thyroid imaging and, 887(ab)
- SNM task force proposes Nuclear Magnetic Resonance Club, N1814
- SPECT and planar scintigraphic imaging temporomandibular joint, 952(ab)
- structure identification and analysis PET, 732(ab)
- Tc-99m SPECT quantitation of infarct size, 986(ab)

**Nuclear medicine**

- Commentary: A one-year sabbatical in Jülich, N1666
- Commentary: Nuclear medicine in a PPO and HMO era, N1516
- drug-radiopharmaceutical interaction screening, 1801(ab)
- IAEA plays major role in promoting nuclear medicine in developing countries, N9
- National Nuclear Medicine Week becomes a U.S. law with President Reagan's signature, N1233
- New European association rises to challenges facing nuclear medicine; European Nuclear Medicine Congress examines clinical demands and efficacy, N1662
- Nuclear medicine community plays expanding role in RSNIA annual meeting; Growth in comparative imaging reflects search for optimal modalities, N319
- Nuclear medicine faces bright future when new diagnostic agents reach market, N1
- correction, misspelled radiopharmaceutical, N170
Nuclear medicine data

Nuclear medicine technologists face changing roles in future health care: Allied health moves toward multicompetency training, N14 nuclear war and, 437(le) quality assurance and, 1366 radiopharmaceutical-chemotherapy drug interactions, 1797(ab) SPECT and PET advances herald new era in human biochemistry; The Society of Nuclear Medicine Scientific Meeting Highlights, N1227

Nuclear medicine data
computer system for long-term storage, 100(ab) Commentary:

Nuclear medicine history
Brookhaven, origin of Tc-99m and F-18 FDG, opens new frontiers for nuclear medicine; LINAC's proton beam energizes unique medical isotope producer, N1507 Commentary: Lines from the president: Tradition, history, and nuclear medicine, N1813 Commentary: Oak Ridge—midwife to nuclear medicine, N158 Itsu Yamamoto receives Berson-Yalow Award for radioassay research, N742 JNM founding editor looks to future of nuclear medicine and medical education, N1097 Medical advances surface from "whirlpool" at the Nuclear Research Center Jülich: Institutes of Medicine and Radiochemistry join forces in scientific progress, N1803 Nuclear medicine milestones at Oak Ridge, N152

Nuclear Medicine Pioneer Award conferred on Rosalyn S. Yalow and Solomon A. Berson: Discovery of insulin antibodies in the 1950s led to radioimmunoassay, N745 Richard Wahl receives Tetalman Award for monoclonal antibody research, N1388 S. James Adelstein,preeminent radiation biologist, chosen for Aebersold Award, N757 Twenty years of nuclear medicine at NIH, N749 U.S. Navy started early technologist training program, alumni meet in Bethesda, N755 William G. Myers retires as SNM historian, honored with Distinguished Educator Award, N751

Nuclear imaging
absolute quantitation radiomunnotherapy, 1004(ab)

Nuclear medicine market
Commentary: Toward a "win-win" relationship, N586 Imaging equipment sales rising in Europe, N328 Nuclear medicine community explores problems of computer/equipment market; SNM Computer Council considers, formulating software guidelines, N585 Report published on immunotherapy market, N450

Nuclear medicine marketing
prospective payment environment, 433

Nuclear medicine physicians
components of professional competence, 863

Nuclear medicine practice
Commentary: Lines from the president: Nuclear medicine on the rise again, N1387 networked human factors engineering, 1070(ab) Nuclear medicine physicians chosen as consultants in relative value scale study, Harvard project expected to change mechanisms for payment of physician fees, N1381 prospective payment environment, 433 Radiation protection groups update recommendations for pregnant women, N1816

Nuclear medicine procedures
routine telephone transmission of studies, 1000(ab)

Nuclear medicine technology
Commentary: Does multicompetency mean competence?, N1106 HHS publishes credentialing rules, N328 National Council Discusses licensure and future of allied health care; SNM Technologist Section offers liability insurance program, N1385 Nuclear medicine technologists face changing roles in future health care: Allied health moves toward multicompetency training, N14 Technologist section completes first survey on impact of DRG's, N588 U.S. Navy started early technologist training program, alumni meet in Bethesda, N755 Nuclear Regulatory Commission (NEC) NRC reports on misadministrations and unannounced safety inspections, N1102

Neuprophilic fluorination
aminopolyether stereospecific synthesis of F-18, 235

Oakiad Associates
Commentary: Oak Ridge—midwife to nuclear medicine, N158 Oak Ridge Associated Universities carries on radiation training and radiation, N160

Oak Ridge National Laboratory
Commentary: Oak Ridge—midwife to nuclear medicine, N158 Demand for isotopes sought by Oak Ridge, N760 Nuclear medicine milestones at Oak Ridge, N157 Oak Ridge National Laboratory incites active nuclear medicine research program: Heart imaging agents form core of ORNL nuclear medicine group, N155 Supply of stable isotopes from Oak Ridge affects radiopharmaceutical production: Budget cuts limit operation of calutrons, N166

Oat cell carcinoma
gallium imaging in, 1032(ab) Obesity morbid gastroplasty, gastric emptying studies, 1686 Obituary Daniel R. Biello, M.D., 1947-1986, N1389 Oleic acid radiodinated tellurium fatty acid high myocardial specificity, 732.4

Oncology
Medical advances surface from "whirlpool" at the Nuclear Research Center Jülich: Institutes of Medicine and Radiochemistry join forces in scientific progress, N1803 Oncology emphasizes strength of nuclear medicine in tissue characterization; European Nuclear Medicine Congress 1986 scientific highlights, N1653 Opiate receptors binding

effect of naloxone, PET, 935(ab) C-11 carfentanil binding following sexual arousal, 1027(ab) graphical evaluation, 955(ab) PET compartmental analysis, 1027(ab) temporal lobe epilepsy, 1027(ab) fast maximum likelihood method region-of-interest values, emission tomography, 895(ab) F-18-cyclofixy PET, 936(ab) occupancy estimation dual detector system, 945(ab) Organoborane no-carrier-added synthesis via I-123 IMP, 1045(ab) Organomercury compounds radiolabeling with, 1165 15-(Orbtio-1-123-phenylpentadecanoic acid metabolic studies coronary artery disease, 891(ab)

Osmum-191
Tr-191m generator system radiation dose characteristics, 1008(ab) Osmum-191/Iridium-191m radionuclide generator system, 380 Osseous metastasis differentiation from benign bone disease Tc-99m MDP imaging, 727

Osteomyelitis
hematogenous pyogenic radionuclide bone imaging in, 1680 In-111 leukocytes, 1675 In-111 oxine WBC accuracy and reliability, 988(ab) three-phase bone scintigraphy In-111 leukocytes and GI-67, 915(ab)

Osteoporosis
absorptiometry peripheral versus axial skeletal, 1648(le) age-specific longitudinal bone loss rates multiple cortical and trabecular skeletal sites, 885(ab) bone mineral densitometric analysis paraplegics, 885(ab) bone mineral density, 885(ab) postmenopausal transmission ultrasound, bone mass quantitating techniques, 908(ab) response to medical therapy, 886(ab) spontaneous and estrogen-caused bone changes early postmenopausal women, 885(ab)

Osteosarcoma
Ga-67 monoclonal antibody, 1021(ab)

Ouabain
thallium uptake and blood flow relations myocardial, 641

Ovarian cancer
colorectal cancer and radioimmunoangiography, practice and tumor uptake, 881(ab) immunotherapy with viral oncosyate In-111 leukocytes, 942(ab)

Oxalate plasma estimate using carbon-14-oxalate, 571(ab)

Oxygen utilization simultaneous measurement, regional cerebral blood flow, 913(ab)

Oxygen-15 labeled carbon dioxide bone marrow blood flow measurement, 946(ab)

1978 The Journal of Nuclear Medicine
Oxygen-15 butanol
preparation
1979 positeon tomography, 834
Oxygen-15 carbon monoxide
Edison lamp, 981(ab)
Oxygen-15 water
myocardial blood flow
dynamic PET, 976(ab)
myocardium perfusion images
new subtraction method, 928(ab)

Peclalitate
myocardial transcapillary transport, 966(ab)

Pancreas
allografts
noninvasive evaluation, 909(ab)
dual-tracer studies of HIPDM and tryptophan,
957(ab)
imaging
1-125 HIPDM, SPECT, 1013(ab)
In-111 leukocyte imaging
pancreatitis, 345

Pancreatitis
In-111 autologous leukocyte imaging, 345

Parathyroid
carcinoma
Ga-67 citrate scintigraphy, 63
imaging
peak TI-201 activity, image reregistration
technique, 963(ab)
localization
radiiodinated toluidine blue, Tc-99m-
thyroid superposition scintigraphy, 963(ab)
localization of tumors
optimized dual-isotope, 962(ab)
scintigraphy
localization, ectopic and transplanted
parathyroid glands, 963(ab)
stimulation of blood platelet kinetics, 965(ab)
Thallium-pertechnetate subtraction scintigraphy
adenomatous and hyperplastic parathyroid
glands, 963(ab)

Parathyroid adenoma
detectability
oral phosphate effects, 1943(le)

Parathyroid glands
hyperparathyroidism
TI-201 and Tc-99m subtraction scanning,
580(ab)

Parathyroid hormone
sensitive assay for, 1039(ab)

Parathyroid imaging
automated comparison of scintigraphy images,
1337
TI-201
tissue uptake and phantom studies, 1262

Parkinson's disease
Carbon-11 MPTP tracer for, 1600
PET, 936(ab)

Peak filling rate
detection of anthracycline cardiotoxicity,
1796(ab)

Penetrate
intravenous
clearance mechanism in animals, 668

Peer review organizations (PROs)
AMA to monitor PRO impact, N1668

Peripheral hemodynamics
radionuclide assessment
myocardial blood flow, 192

Peripheral vascular disease
reconstructive surgery
TI-201 lower limb perfusion before and after,
1035(ab)
Pertechnetate
excretion
breast milk, radiation dosimetry from, 1569
transport
human erythrocyte membrane, 946(ab)
PET. See Positron emission tomography

Phase analysis
regional wall abnormalities
radionuclide angiograms, coronary and
noncoronary artery disease, 781

Phaeochromocytoma
detection
I-131 MIBG, CT/MRI correlation, 1010(ab)
diagnosis
I-131 MIBG and CT imaging, 929(ab)
I-131 MIBG for locating, 1222(le)
kil-form analog of metaidobenzyguanidine,
256
malignant potential, 908(ab)
sympathoadrenal imaging agents
comparison, 1138

Phaeochromocytoma, metastatic
I-131 metaidobenzyguanidine metabolism in,
37

Phaeochromocytomas
transplanted
alpha amino acid uptake, PET, 1043(ab)

Phosphate
oral
detectability of parathyroid adenoma,
1943(le)

Phosphonic acid
serine analog
Tc-99m-labeled, bone uptake, 847

Phosphorus-35
colloidal chronic phosphate
957(ab)
cystic brain tumors, 1503(le)
radiation dosimetry
cystic-type tumors, 1501(le)

Phosphorus-31 NMR
glioma
chemotherapy effects, 970(ab)

Picture archiving and communications systems
(PACS)
Guidelines for PACS published, N442

Planar imaging
TI-201 SPECT or
experimental infarct size, 968(ab)

Plasma
clearance
synthesis of continuous infusion, kidney,
1611

Platelets
antiplaetelet Mab
labeling and characterization, 958(ab)
fibrinogen deposition and
effect of vitamin E, thrombosis, 947(ab)
function
In-111, granulocyte-platelet concentrates,
946(ab)
In-111 directed therapy
cyclosporine renal arteriopathy, 964(ab)
In-111
tropolone versus oxine, 1669
Indium-labeled monoclonal antibody, 975(ab)
kinesics
mathematic models, 1192
new kit method for labeling
Tc-99m, 946(ab)

Pleural effusion
peritoneo-pleural communication, 1706

Pneumocystis carinii pneumonia
early detection in AIDS patients
comparison of Tc-99m DTPA aerosol and
gallium scans, 951(ab)

Polyethylene
monoclonal antibodies labeled with, 1043(ab)

Portal-systemic circulation
Tl-201 per-rectal administration, 1010(ab)

Portasystemic shunt
fraction quantification
colonic I-123 IMP, 1321

Positron tomography
alpha amino acid uptake
transplanted phaeochromocytomas, 1043(ab)
assessment of coronary reserve
compared to coronary arteriography, 943(ab)
axial sampling density requirements, 1003(ab)
behavioral states
reproducibility of metabolic pattern, 1025(ab)
benzodiazepine binding sites
brain, 1593
blood-brain barrier permeability, 1024(ab)
flow agents for
brain, 532
brain
aging and dementia, 945(ab)
flow agent and MAO indicator,
1048(ab)
functional development, 901(ab)
functional relationships, 945(ab)
C-11 carfentanil binding to opiate receptors
comparmental analysis of, 1027(ab)
C-11 CO2 method
cardiac imaging without a cyclotron Rb-82
diagnosis of coronary artery disease,
976(ab)
evaluation, brain, 969(ab)

C-11 dopa synthesis
brain, 1046(ab)

C-11 CGP 12177
beta adrenergic receptors, 949(ab)
C-11 leucine cerebral protein synthetic rate
technical and modeling considerations,
955(ab)

C-11-L-methionine
growing of brain tumors, 890(ab)

C-11-methionine and F-18-deoxyglucose
brain tumors, 890(ab)

C-11 thymidine as imaging agent, 1033(ab)
Cardiology meeting in Japan examines PET
applications in coronary artery disease;
Kyoto University PET Center pursues
routine clinical PET studies, N1383
causative hypometabolism
Huntington's disease, 920(ab)
cerebral glucose utilization
amyotrophic lateral sclerosis, PET, 920(ab)
cerebral malignancy
C-11 putrescine and deoxyglucose, 889(ab)
cerebral metabolism
olivopontocerebellar atrophy, 2-FDG, 920(ab)
chronic cocaine users
cerebral blood flow, 921(ab)
chronic ischemic heart disease
severity of segmental myocardial blood flow
reduction, 891(ab)
circular harmonic transform algorithm
X-ray CT, 1003(ab)
collateralized myocardium
coronary steal, noninvasive PET, 977(ab)
comparison of images
integrated projection technique, fixed
distribution volume, 1004(ab)
coronary angioplasty, 977(ab)
correction of random coincidences, 973(ab)
data analysis
Pre-excitation syndrome

noisy input function, 980(ab)
dueteriogluucose
alteration of biodistribution, 388
dopamine
improved delineation of, 1878
dopamine receptors
fluorine-118 FPSP binding to, 1047(ab)
D-2 dopamine receptor density, 954(ab)
design and preliminary results from posicam, 973(ab)
determination of LCBF
evolution of partial seizures, temporal lobe
epilepsy, 902(ab)
Donner 280-crystal
exercise vs. rest studies, 976(ab)
doubling PET counts
maximum-count-rate-dynamic-energy-
windowing, 973(ab)
3-D surface mapping
heart and brain, 91(ab)
dynamic
comparison of rapid parameter estimation
and individual parameters, 940(ab)
dynamic studies of heart
temporal information for spillover correction, 980(ab)
effect of naloxone
opiate receptor binding, 935(ab)
effects of amphetamine
local cerebral metabolism, normal and
schizophrenic subjects, 901(ab)
effects of increasing scanner resolution
neurological data variability, 1001(ab)
fast maximum likelihood method
region-of-interest values, 895(ab)
FDG configuration model
estimates of cerebral glucose metabolism.
940(ab)
FDG kinetic model
mapping of rate constants, 1001(ab)
F-18-N-methylspiroperidol
antipsychotic drug D-2 receptor,
schizophrenics, 880(ab)
flood phantoms to evaluate quantification of,
1024(ab)
fully automated data processing
dopamine D-2 receptors, 1002(ab)
Ga-67 EDTA
blood-brain barrier, 1074(ab)
Gl-68 colloid tomographic liver imaging,
890(ab)
glucose transport
brain, 1867
glucose utilization
non-gliomatous neoplasms, 901(ab)
high resolution cameras
new dual crystal depth sensitive detector,
974(ab)
Huntington's disease, 1074(ab)
image reconstruction, 1790(ab)
image resolution
functional brain responses beneath, 1025(ab)
imaging of MPPIT-induced change, 879(ab)
imaging of thyroid using I-124, 909(ab)
interpolating scan and oblique-angle tomograms
coronary artery diseases, N-13 ammonia,
901(ab)
intra-arterial and intravenous [14C]BCNU
pharmacokinetics, 775
I-123 IMP
diagnosis of Alzheimer's disease, multiple
infarct dementia, 769
Kety-Schmidt single-compartment model
CBF measurements, 91(ab)
labeling of proteins with F-18, 982(ab)
Lesch-Nyhan syndrome
dopamine receptors in, 1027(ab)
ligand 18F-cyclofoxy
opiate receptor, 936(ab)
ligands C-11 SCH 23390 and C-11 raclopride
dopamine D-1 and D-2 receptors, 879(ab)
local cerebral blood flow
examination of assumptions, 1003(ab)
measurement of glucose metabolism
cerebral, 1358
metabolic and hemodynamic studies of glomas,
889(ab)
MRI comparison
cerebrovascular disease, 1026(ab)
MRI and XCT
head trauma, 91(ab)
myocardial
blood flow measurement, H214O, 976(ab)
nitrogen-13 ammonia, 1830
neuro-pet studies
F-18, 1048(ab)
new measurement method
regional cerebral blood flow, 912(ab)
N-13-labeled cisplatin
microscale synthesis, 399
N-13 glutamate uptake and perfusion
effect of methotrexate, Walker-256
carcinoma, 970(ab)
O-15-H2O
cerebral blood flow alteration, simple phobic
anxiety, 901(ab)
Parkinson's disease, 936(ab)
pair partition coefficient values for water, 941(ab)
patients at-risk for Huntington's disease
brain metabolism, 18F-FDG, 920(ab)
plasma sampling times
input function, deoxyglucose method, 999(ab)
post-ischemic myocardium
glucose metabolism, 890(ab)
position-sensitive detectors
brain and heart, 90
preparation of F-18 fluoroethylspiperone
evaluation as D-2 receptor ligand, 928(ab)
preparation of O-15 butanol, 834
production of Zr-89
antibody imaging, 983(ab)
protein synthesis
brain, l-tyrosine measurement of, 1049(ab)
random coincidence
deadtime correction method, 1925
regional glucose metabolism
coronary anatomy, 967(ab)
regional myocardial blood flow
hypertrophic cardiomyopathy, 933(ab)
renal blood flow
Rubidium-82, 941(ab)
response function for the ECAT3 positron
camera, 974(ab)
rubidium-82
coronary occlusion, 1456
myocardial blood flow, 976(ab)
myocardial infarction, 1824
scatter measurements
dual energy windowing, 883(ab)
Scientists advocate using empirical data from
physiologic PET and SPECT images:
Radiopharmaceutical chemists explore
current views on radiotracer design, N1093
seizures or hallucinations
brain, I-123 IMP detection, 1029(ab)
sequential
salvage of reperfused myocardium, 732(ab)
serotonin receptor radiotracer
C-11 N-methyl-keratanserin, 983(ab)
serotonin receptors
lung phagocyte recruitment, cigarette
smoking, 950(ab)
simultaneous measurement regional cerebral
blood flow, oxygen utilization, 913(ab)
slanting light-guide detection system, 973(ab)
SNM initiates efficacy study of RIA test and
takes action on PET reimbursement; Board of
Trustees endorses new standing
committee on efficacy, N1238
SPECT and PET advances herald new era in
human biochemistry; The Society of
Nuclear Medicine scientific meeting
highlights, N1227
stability of O-15 steady state technique, 912(ab)
static and dynamic protocols
muscarnic cholinergic receptor binding,
936(ab)
stress-induced myocardial ischemia
increased fluoroexyglucose accumulation,
936(ab)
structure identification and analysis
MRI images in, 732(ab)
TI-201 myocardial imaging
dipyraridamole-induced coronary vasodilation,
31
time-of-flight
designing of computer system, 1000(ab)
treatment of axial data, 917(ab)
turnover of MAO-B
brain, 982(ab)
two sets of metabolic data
fluoroexyglucose and, 733(ab)
viable myocardial segments
fixed thallium perfusion defects, 932(ab)
phosphate-shaped scintillation crystals, 99
white matter disorders, 889(ab)
Pre-excitation syndrome
length-based Fourier analysis in, 1131
Preferred provider organizations (PPOs)
Commentary: Nuclear medicine in a PPO and
HMO era, N1516
Pregnancy
bone and gallium scintigraphy, 370
Radiation protection groups update
recommendations for pregnant women,
N1816
term
digoxin-like substance in, 1418
Propranolol
thalium uptake and blood flow relations
myocardial, 641
Propranolol hydrochloride
tumor perfusion and Ga-67 uptake
sarcoma, mouse, 243
Prospective Payment Assessment Commission
(ProPAC)
ProPAC issues report on the NMR
reimbursement, N450
Prospective Payment System (PPS)
prospective payment environment, 433
Technologist section completes first survey on
impact of DRGs, N588
Prostate
adenocarcinoma, 1049(ab)
design hypertrophy
impotence and, xenon-133 washout, 1036(ab)
cancer
PAY-276 imaging and kinetics, In-111 Mab,
1020(ab)
carcinoma
skeletal scintigraphy, 582(ab)
imaging using MRI/CT/US, 948(ab)
lymphoscintigraphy
tc-99m sb-sc, 1034(ab)
metastatic cancer
PAA-276 antibody, ln-111, 1021(ab)
metastatic carcinoma
Tc-99m DMSA uptake, 1223(le), 1224(le)
routine bone scintigraphy, 948(ab)
Prostatic carcinoma
skeletal metastasis, 1786(le)
Protein
synthesis
brain, measurement with L-tyrosine, 1049(ab)
Protracers
mapping central catecholamine stores, 1076(ab)
Pseudomyxoma serosa
considerations for radiotherapy
IP-I-131 B72.3, 1021(ab)
Pulmonary embolism
detection of sclerosant, 956(ab)
diagnosis, V/Q scintigraphy, 922(ab)
diagnostic utility, Tc-99m DTPA aerosol/Tc-99m MAA lung scintigraphy, 923(ab)
monoclonal antibody comparison, 923(ab)
perfusion and ventilation perfusion patterns, 568(le)
planar imaging
SPECT, 1075(ab)
radioaerosol penetration, 1037(ab)
xenon and krypton studies, 1391
Pyelonephritis
MRI
children, 577(ab)

Quality assurance
gamma camera images, 820
nuclear medicine and, 1366
Quality assurance programs sought, N1242
Radiation dose
absorbed profiles, renal transplant patients, 980(ab)
bladder wall
F18-fluorodeoxyglucose, 899(ab)
dosimetry and biological distribution
Tc-99m MAA, 1008(ab)
I-131 monoclonal antibodies
19-9/anti-CEA and ox 125, 1019(ab)
I-131 OIH and Tc-99m MAG3, 898(ab)
in skin, contamination of In-111 oxinate, 1007(ab)
serial distribution
Yt, 90, small sources, 1007(ab)
tracers for cell labeling
In-111 leukocytes, radiation dosimetry, 979(ab)
Radiation dosimetry
Tc-99m-labeled lymphocytes, 105
Radiation physics
International Radiation Physics Society
founded, N1108
Radiation, risk of
Cancer screening to study fallout effects, N1390
Computer program for epidemiologic tables, N1390
Conference on radiation emergencies, N1518
New dosimetry changes atomic bomb data, N1242
Radiation protection groups update recommendations for pregnant women, N1816
Radioactive waste, low-level
Low-level compact pass by vote of 378-0, N16
Passage of low-level waste amendments shifts focus to state legislatures, N447
Radioactivity
measurement with external monitoring versus urine assay, 1071(ab)
Radiosurgery
microwave clearance assessment, tracheobronchoplasty, 1397
Tc-99m DTPA clearance
respiratory failure and, 1037(ab)
Radioenzymatic assay
urinary salsolinol, 893(ab)
Radiogrammetry
bone changes, 1540
Radioimmunodiagnosis
localized bacterial infection, 915(ab)
Radioimmunoassay (RIA)
automated, thyroid, 1623
Itso Yamamoto receives Benson-Yallow Award for radioassay research, N742
Nuclear Medicine Pioneer Award conferred on Rosalyn S. Yalow and Solomon A. Berson; Discovery of insulin antibodies in the 1950s led to radioimmunoassay, N745
Schilling test replacement, 892(ab)
serum vitamin B12 levels, racial dependence, 892(ab)
SNM initiates efficacy study of RIA test and action on PET reimbursement, Board of Trustees endorses new standing committees on efficacy, N1238
triiodothyronine in serum, 1702
tumor marker, breast carcinoma, 1039(ab)
Radioimmunodetection
colon and gastric cancer xenografts, 1022(ab)
lung cancer-anti-CEA monoclonal antibody, 881(ab)
Radioimmunostaining
dual-labeled monoclonal antibody, 1293
tumor xenografts
monoclonal antibodies, 1739
Radioimmunoscintigraphy
ECT compared to TCT, 880(ab)
practice and tumor uptake, 881(ab)
Radioimmunotherapy
B-cell lymphoma, L-131 ILYM-I Mab, 903(ab)
Bi-212 labeled monoclonal antibodies in, 1040(ab)
colon cancer xenografts, anti-CEA antibody, 897(ab)
comparison with 4 MV external beam radiotherapy, tumor xenografts, 902(ab)
I-131 monoclonal antibodies, 19-9/anti-CEA and ox 125, 1019(ab)
colon carcinoma xenografts, 1019(ab)

novel strategy
microdosimetric and compartmental analysis, 898(ab)
nuclear medicine images
absolute quantitation, 1004(ab)
T-cell leukemia
bismuth-212 labeled anti-TAC monoclonal antibody, 897(ab)
Radiolactone
extrathyroidal metabolism, 150(le)
Radiolactone
excretion
breast milk, radiation dosimetry from, 1569
monoclonal antibodies, 939(ab)
urinary metabolites
fibrinogen, 958(ab)
Radiological Society of North America (RSNA)
Nuclear medicine community plays expanding role in RSNA annual meeting; Growth in comparative imaging reflects search for optimal modalities, N319
Radioiodine-anesthetic flow study, 1487
Radioiodine angiographic phase analysis, coronary and noncoronary artery disease, 781
Radioiodine generator system
osmium-191/iridium-191, using activated carbon, 380
Radioiodine imaging
correlation with diagnostic ultrasound scrotal diseases, 1774
Radiopharmaceutical development
FDA orphan drug program ready to aid radiopharmaceutical investigators, N743
Scientists advocate using empirical data from physiologic PET and SPECT images; Radiopharmaceutical chemists explore current view on ratiodiact design, N1093
U. S. Senate passes bill for export of drugs awaiting FDA approval, N1108
Radiopharmaceuticals
albump biodistribution, 942(ab)
comparison, 572(ab)
dosage selection, pediatric nuclear medicine, 287
preparation, analysis of robotics, 714
Private sector plans to set standards for radiopharmaceutical calibration, N1517
Reported adverse reactions to radiopharmaceuticals remain low in 1984, N327
Radiophosphate
subperiosteal bone formation, renal osteodystrophy, 1572
Radiotherapy
pseudomyxoma peritonei, 1021(ab)
Radiothyronines
acute toxicity to vehicle, 1942(le)
Radiotoxicity
Tc-99m-labeled lymphocytes, 105
Receiver operating characteristic (ROC) analysis
comparison between SPECT and Planar imaging, 978(ab)
optimum filter function, SPECT imaging, 1002(ab)
Receptor imaging
PET static and dynamic protocols, 936(ab)
Receptors
alpha-1 adrenergic labeling, I-125 HEAT, 969(ab)
beta-adrenergic C-11 CPG 12177, 949(ab)
density, quantitative assay, 949(ab)
mucairetin, AHC-receptor system, INQB, 937(ab)
serotonin
lung phagocyte recruitment, 950(ab)
Red blood cells
Tc-99m labeling, 1770
volume and blood volume, 1013(ab)
Reflux
sympathetic dystrophy bone scintigraphy, children, 932(ab)
skeletal scintigraphic findings, children, 932(ab)
Reflux
manometric quantitative nuclear cistography, 918(ab)
Reflux uropathy
renal function evaluation with I-123 hippuran, 582(ab)
Regional wall motion
abnormalities
radionuclide equilibrium gated studies.
prediction of death, myocardial infarction, 926(ab)
superimposition of standard radiographs, 1343
TC-DMSA
renal cortical infarction, 918(ab)
TC-99m IDA
primary biliary cirrhosis, primary sclerosing cholangitis, 1012(ab)
Tc-99m-thyroid superposition
parathyroid localization, 963(ab)
testicular torsion, 1053(ab)
TI-201
prediction of death, myocardial infarction, and chest pain, 1842
recurrent medullary thyroid carcinoma, 1564
regional flow disparity, 75
TI-201 arm vein uptake
exercise, 1353
three phase bone
In-111 leukocyte imaging and Gallium-67, osteomyelitis, 915(ab)
thyroid imaging
correlative MR, 887(ab)
total-body
Tc-99m thyroid carcinoma, 1854
Scintillation cameras
see also Gamma cameras
bone scintigraphy
osteomyelitis, 566(le)
digital gamma
high count rate first pass radionuclide angiography, 198
flood field uniformity and spatial resolution
asymmetric photpeak window effects, 706
gamma camera quality assurance images
moiré interference, 820
impact of radiocontaminants
1-123
iterative attenuation correction in SPECT
attenuation coefficients, transmission measurements, 1004(ab)
liver transplant function, 451
position-sensitive detectors
brain and heart, 90
quality of nuclear medicine imaging
developing countries, IAEA study, 1019(ab)
radiative iodine uptake
breast, 149(le)
SPECT Compton-scattering correction analysis,
spatially-dependent energy spectra, 900(ab)
use of germanium detector
scatter correction in SPECT, 883(ab)
use of NEMA standard
in-field acceptance testing, 1017(ab)
weighted acquisition
improved bone and gallium images, 988(ab)
weighted acquisition using finite spatial filters
real-time scatter removal, 960(ab)
Scintillation crystals
wedge-shaped
positron tomography, 99
Sclerotectomy
detection of sclerosant
pulmonary embolization, esophageal varices, 956(ab)
Scrotal disease
diagnostic ultrasound
radionuclide imaging correlation, 1774
Scrotum
urine extravasation, 807
Scintiscanning
gastroesophageal, 1212
Selenium-75 pereglide
distribution in brain
dopamine receptor agonists and antagonists, 906(ab)
Semiconductor detector
cerebrospinal fluid shunt assessment, 1025(ab)
Tc-99m IDA
phosphonic acid analog
Technetium-99m-labeled, bone uptake, 847
Sestaonin
reuptake
serotonin-2 receptor binding, H3-N-methylspiperone, 936(ab)
S2 receptor
binding, depression following stroke, 1074(ab)
Serotonin receptors
lung phagocyte recruitment
cigarette smoking, PET, 950(ab)
radiotracer C-11 N-methyl-ketanserin
PET, 983(ab)
Serum
collection effects
labeling efficiency of In-111 chelates, 104(ab)
Shock wave lithotripsy
pre- and postintracorporeal renogram in, 582(ab)
renal function after
MRI, 577(ab)
Simulation
MRI pulse sequence parameters
optimal tissue contrast, 281
Single photon emission computed tomography (SPECT)
acquisition and reconstruction, 1717
Anger camera
performance changes, 1902
area weighted approach to attenuation correction
arbitrarily-shaped nonuniform attenuation maps, 884(ab)
assessment of TI-201 late redistribution
exercise myocardial SPECT, 900(ab)
automated body contour detection, 1184
axial aperture, 930(ab)
flow
cerebral vascular disease and, 1029(ab)
flow-blood to-blood volume imaging
cerebral, 1938(le)
brain imaging agent
radioactive iodinated 8-OH-DPAT, 972(ab)
CAT or
evaluation, liver disease, 924(ab)
cerebral blood flow
schizophrenic patients, 734(ab)
circular harmonic transformation algorithm, 735(ab)
collimators
comparison with I-123 antibodies, 1467
collimator selection
brain imaging, 1729
comparison of spatial resolution
180° vs. 360° SPECT imaging, 1016(ab)
comparison with planar imaging
Tc-99m MDP bone scan, malignant otitis externa, 978(ab)
TI-201, coronary artery disease, 999(ab)
Compton-scattering correction analysis,
spatially-dependent energy spectra, 960(ab)
cone-beam
validation, conventionally-designed converging collimator, 930(ab)
convolution reconstruction algorithm
astigmatic collimator imaging, 896(ab)
correction of I-131 uptake-vs-time curves, 898(ab)
3-D analysis of gated blood-pool studies, 918(ab)
I-D and 2-D scatter deconvolution techniques, 884(ab)
definition of normal limits
stress TI-201 myocardial rotational tomography, 899(ab)
diffuse hepatocellular disease, 616
digital restoration of images
medium-to-high energy photon emitters, 735(ab)
dynamic
hepatobiliary imaging, via time-shifting, 980(ab)
electronic collimation
high energy single photons, 931(ab)
ethics and economics, 145(le)
180° exercise TI-201
diagnostic accuracy, chest pain syndrome, 999(ab)
experimental infarct size
TI-201 SPECT or planar imaging, 968(ab)
fan beam collimator
imaging of the head, 810
Fourier analysis
epichardiac pacing, Wolff-Parkinson-White syndrome, 993(ab)
gamma camera based systems
poison noise for, 1070(ab)
head tilt and effect on resolution orthogonal transverse slices, 960(ab)
hepatic hemangiomias, 925(ab)
high sensitivity
astigmatic collimator, brain, 930(ab)
I-123-iodoamphetamine and Xe-133 SPECT and PET
chronic cerebral infarcts, 888(ab)
I-131-iodozenbaryltrimethylphosphonium acetate
synthesis and biological properties, 971(ab)
I-123 labeled monoclonal anti-CEA fragments
ECT detection of colorectal cancer, 880(ab)
image distortion in, 1792(le)
imaging of cardiac transplant rejection
In-111 antimyosin antibody, 910(ab)
imaging of liver/spleen and brain, 1001(ab)
imaging with fan beam collimators, 930(ab)
improved SPECT
simultaneous transmission and emission tomography, 884(ab)
In-111 and I-123 images
digital restoration of, optimized Metz filters, 1327
initial experience with Tc-99m HMPAO,
887(ab)
inverse Monte Carlo image reconstruction
maximum likelihood estimation, 895(ab)
I-123 IMB measurement
cerebral ischemia, 1028(ab)
iterative attenuation correction
attenuation coefficients, transmission measurements, 1000(ab)
knot-form analog of MIBG, 256
left ventricular volume determination, 911(ab)
leg muscle perfusion study, 1035(ab)
lesion detectability
photon count dependent resolution recovery filtering, 981(ab)
liver imaging
iterative attenuation correction algorithm, 701
lung perfusion physiology, 1038(ab)
radiouclide concentrations and, 1799(ab)
Single-plasma sampling technique

TI-201 mass attenuation and energy absorption
human tissues, gamma ray energies, 1007(ab)
measurement of collimator hole angulation
camera head tilt, rotating camera, 961(ab)
measurement of rCBF
Tc-99m, 905(ab)
molecular focus
ring SPECT systems, 1017(ab)
Monte Carlo simulations
experimentally-measured scatter fractions, 960(ab)
myocardium, 146, 147(le)
necessity of radionuclide liver scan
hepatocellular carcinoma, 1012(ab)
new 3-D technique, 917(ab)
NMR and planar scintigraphic imaging
temporomandibular joint, 952(ab)
nodular regenerative hyperplasia
liver, 56,le)
onuniform attenuation correction
reconstruction algorithms, 1070(ab)
opimization of imaging time and filter
selection, 736(ab)
opimum filter function, 1002(ab)
pancreas imaging
1-123 HIPDM, 1013(ab)
parallel beam and fan beam comparison, contrast-detail lesion
detectability, 930(ab)
perfusion and receptor SPECT in the dementias
George Taplin Memorial Lecture, 855
PET and
functional image analysis, 944(ab)
planar imaging
circular harmonic transform algorithm, 893(ab)
recovery coefficients, quantitative imaging of
small objects, 1005(ab)
regional cerebral blood flow, 171
regional cerebral blood flow, 732(ab)
regional phase mapping
gated nuclear angiography or tomography,
ventricular tachycardia, 992(ab)
renal volume estimation
phantom study validation, 1006(ab)
ring detector
improvement of spatial resolution, cerebral
diffusion flow, 1018(ab)
scatter correction
use of germanium detector, 883(ab)
small field isotope, 884(ab)
Scientists advocate using empirical data from
physiologic PET and SPECT images;
Radio pharmaceuticals also explore
new current view on radionuclide tracer design, N1093
serial TI-201
assessment of therapy, acute myocardial
infarction, 996(ab)
sites of pulmonary hemorrhage
fistulous, 923(ab)
SKF-103108A biodistribution
D-1 receptor site imaging agent, 906(ab)
"smear" artifact
180° imaging, 961(ab)
SNM publishes books on SPECT and MIRD;
New primers cover fundamental concepts
and methodology, N756
SPECT and PET advances herald new era in
erial medicine; The Society of
Nuclear Medicine Scientific Meeting
Highlights, N1227
stress-redistribution TI-201
localization, coronary artery disease, 997(ab)
studies of dopamine receptor
2′-iodospiroperidol, 972(ab)
target detection, 1006(ab)
Tc-99m complexes
brain, 1051(ab)
Tc-99m DMlSA
evaluation of children with reflux, 919(ab)
Tc-99m HMPAO
cerebrovascular disease, 888(ab)
TI-201
exercise loading, 999(ab)
TI-201 imaging
myocardial contusion, 998(ab)
TI-201 oral dipyrindamole
assessment of coronary artery stenosis, before
transluminal angioplasty, 944(ab)
TI-201 redistribution
normal males, 998(ab)
tomographic reconstruction
inverse Monte Carlo, 1577
“upward creep” of the heart
TI-201 stress-redistribution, 899(ab)
volume estimation
edge enhancement and volume projection,
917(ab)
Single-plasma sampling technique
etermination of glomerular filtration rate by
radioiodinated diatrizoate injection and, 45
SKF-103108A biodistribution
D-1 receptor site-specific imaging agent,
906(ab)
SN(H) ions
concentration
Tc-99m red blood cell labeling and, 1202
Society of Nuclear Medicine (SNM)
Commentary: Lines from the president, N754
Commentary: Lines from the president:
Tradition, history, and nuclear medicine,
N1813
Commentary: Lines from the president: Nuclear
medicine on the rise again, N1387
Commentary: Lines from the president, N441
Investigators increase abstract submissions to
SNM 33rd Annual Meeting in 1986;
Technologist Section offers liability insurance program,
N1385
Nuclear medicine community explores
problems of computer/equipment market;
SNM Computer Council considers
formulating software guidelines, N585
Publications director leaves SNM to head
journal division of publishing firm, N445
Quality assurance programs sought, N1242
SNM initiates efficacy study of RIA tests and
takes action on PET reimbursement; Board
of Trustees endorses new standing
committee on efficacy, N1238
SNM members propose Brain Imaging Council,
N760
SNM plans to publish more educational tools,
N1390
SNM publishes books on SPECT and MIRD;
New primers cover fundamental concepts
and methodology, N756
SNM 33rd Annual Meeting draws thousands to
Washington for scientific communication;
Categorical seminars offered on future
directions of nuclear medicine, N739
SNM scientific exhibits receive awards, N1668
SNM takes first step in enhancing
representation of non-U. S. members;
Board of Trustees discusses SNM
reorganization and other action items,
N589
SNM task force proposes nuclear magnetic
resonance club, N1814
SNM Winter Meeting presents metabolic
imaging and financial analysis;
Instrumentation manufacturers plan users
group meetings, N169
SNM Winter Meeting to cover perfusion
imaging, N1667
SPECT and PET advances herald new era in
human medicine; The Society of
Nuclear Medicine Scientific Meeting
Highlights, N1227
SPECT, PET, and NMR at SNM winter
meeting, N16
Technologist Section completes first survey on
impact of DRG's, N588
Solomon, Nathan A.
in memoriam, 869(le)
Spatial resolution
high
distal tomography, 99
SPECT: see Single photon emission computed
tomography
Sphincterotomy
endoscopic
quantitative hepatobiliary imaging, 937(ab)
Spine
bone mineral density, 907(ab)
Spiroperidol
derivatives
brain uptake, dopamine receptors, 879(ab)
Spleen
identifying hepatocellular disease
measurement of spleen/liver ratio, 1012(ab)
SPECT imaging, 1001(ab)
splenectomy
splenic size in hepatoportal ischemia,
1013(ab)
visualization with heat denatured Tc-99m RRC
impaired reticuloendothelial system, 965(ab)
Splenic hemangiomas
presentation as “hot spot”
radionuclide scintigraphy, 804
SQ 30217
Tc-99m-labeled myocardial imaging, 1051(ab)
Stable isotopes
see Isotopes, stable
Stannous glucosephosphate
blood cell labeling, 1052(ab)
Stereoisomers
Technetium-99m MAG3
relation between structure ad renal transport,
894(ab)
Stippled ribs
bone scan interpretation, and, 216
Stomach
massive uptake of Tc-99m MDP
in vitamin D intoxication, 219
Stress
effect of exercise position
cardiac and pulmonary thallium kinetics,
coronary artery disease, 788
Sympathetic neuronal function
chronic volume-overload heart failure
impaired myocardial retention of I-131
MI, 1068(ab)
Sympathoadrenal imaging agents
comparison, 1138
T
Tantalum-178
W-178 and
dosimetry, adults and children, 1009(ab)
Technetium-99m
blood cell labeling
stannous glucoheptonate, 1052(ab)
bone scintigraphy
osteomyelitis, 566(le)
Brookhaven, origin of Tc-99m and F-18 FDG,
opens new frontiers for nuclear medicine;
LINAC's proton beam energizes unique
medical isotope producer, N1507
complexes
brain blood flow imaging, 1050(ab)
hexhalothetenate reagents in synthesis,
1049(ab)
metal ion complex compounds for preparation of,
1050(ab)
N2S2 ligands, 1051(ab)
polyaminodithiol derivatives, 1050(ab)
synthesis via p-methoxybenzyl protected thiol
ligand, 1050(ab)
labeled lymphocytes
radiotoxicity study, 105
labeled phosphonic acid analog of serine
bone uptake, 847
labeled RBC
forearm blood flow and volume, 192
labeling
red blood cells, 1770
localization of parathyroid tumors
optimized dual-isotope, 962(ab)
lung scintigraphy, 361
MDP
massive uptake in stomach, vitamin D
intoxication and, 219
myocardial perfusion agents
dogs and humans, 409
radiolabeling of antibodies
N2S2 ligands, 957(ab)
radiouclide scanning
giant cell tumor, bone, 329
red blood cell labeling
Sm(I) ion concentration and heparin effects, 1202
skeletal scintigraphy
correlation with In-111 leukocytes, infected
total hip prostheses, 1800(ab)
subtraction imaging
hyperparathyroidism in renal osteodystrophy,
580(ab)
thallium and
false-negative subtraction scintigraphy, 564(le)
uptake
myocytes, 404
uterine blush
multiphase bone imaging, 51
Technetium-99m albumin
protein-losing enteropathy, 1710
Technetium-99m albumin colloid
scintigraphy
gastric emptying and reflux, 1800(ab)
Technetium-99m albumin microspheres
high resolution scintigraphy
myocardial blood flow, 1586
Technetium-99m albumin succinate
eosophageal ulcerations, 1143
Technetium-99m antifibrin
imaging of thrombi, 975(ab)
Technetium-99m antimony sulfide colloid
chyllothorax on, 1783(e)
Technetium-99m BIDA
biliary scintigraphy
jaundiced patient, 1407
Technetium-99m bis(urene)
new myocardial agent
low plasma binding, fast blood clearance, 894(ab)
Technetium-99m cholesterol
dental gland imaging, 916(ab)
Technetium-99m compounds
renal vascular transit time, 1006(ab)
Technetium-99m CPI
myocardial imaging, 878(ab)
Technetium-99m DADT
serum stability
nonspecific binding and, 1051(ab)
Technetium-99m-d, HPM-PAO
brain imaging, 1028(ab)
cerebral blood flow imaging, 1050(ab)
cerebral blood flow tracer
autoradiography, 1074(ab)
comparative tissue uptake, 1052(ab)
regional brain perfusion, 1819
Technetium-99m DSIDA
alteration of kinetics as a function of time,
937(ab)
assessment of liver transplant function
deconvolutional analysis, 1031(ab)
biliary nonvisualization
sensitivity and positive predictive index,
total biliary obstruction, 883(ab)
hepatobiliary and excretory cholecodochogram,
938(ab)
hepatobiliary scintigraphy
clinical efficacy and cost-effectiveness, 883(ab)
hepato cellular uptake, 938(ab)
neonatal cholestasis
hepatobiliary scintigraphy, 931(ab)
Technetium-99m DMS
Detection of glomerular lesions, 502
soft tissue tumors, 1033(ab)
Technetium-99m DMSA
abnormal uptake
malignant tumors, 1032(ab)
injured kidney
failure to visualize with, 377
renal handling, 1943(le)
scintigraphy
renal cortical infarction, 918(ab)
SPECT imaging
evaluation of children with reflux, 919(ab)
uptake
metastatic carcinoma, prostate, 1223(le),
1224(le)
Technetium-99m DTPA
aerosol
delivery efficiency, lung, 1500(le)
captopril challenge
2 kidney and 1 kidney Goldblatt
hypertension, 961(ab)
detection of glomerular lesions, 502, 513
Technetium-99m HMPAO
glomerular filtration
Gates'method, 1644(le)
severe renal disease, 573(ab), 928(ab)
intracranial infection
AIDS-related, 498
intradermal administration
alternative to Xe-133, tissue viability and flow
direction, 975(ab)
localization
neurofibromata, 143(e)
lung clearance of
exercise effects, 274
pulmonary clearance
lung volume and, 1037(ab)
respiratory failure and, 1037(ab)
quality control, 560
quantitative analysis
background correction for, 1070(ab)
radiosurgery
lung perfusion, 1075(ab)
renal imaging
bilateral urothorax identified by, 56
renal clearance estimation
without blood samples, 574(ab)
renal transfer function, 574(ab)
renal transit time, 574(ab)
SPECT imaging with para-axial
neurofibromatosis, 932(ab)
ureteroceles and duplex renal systems, 919(ab)
Technetium-99m DTPA aerosol
comparison with gallium scans
Pneumocystis carinii pneumonia, AIDS,
951(ab)
lung clearance
pigeon fanciers, serum antibody levels,
950(ab)
suspected pulmonary embolism, 1391
Technetium-99m GHA
detection of glomerular lesions, 502
Technetium-99m glucoheptonate
biliary properties of, 1647(le)
Technetium-99m granulocytes
abcess detection, 555
Technetium-99m HDP
skeletal scintigraphy
infected total hip prosthesis, In-111
leukocytes, 977(ab)
Technetium-99m hexakis-aliphatic isonitriles
myocardial uptake and retention
specificity, 959(ab)
regional distribution
ischemic hearts, with/without perfusion,
994(ab)
Technetium-99m HMDP
degraded bone image quality, 1067(ab)
sequential Ga-67 citrate imagine
painful prothesis infection, 1413
serial bone scans
chemotherapy, osteogenic sarcoma, 987(ab)
Technetium-99m HMPAO
blood-brain transfer
parietal cortex, 888(ab)
brain SPECT imaging
early detection of cerebral infarction, 888(ab)
characterization
rCBF imaging agent, autoradiography,
905(ab)
clinical reliability of SPECT, 887(ab)
marker of CBF, 905(ab)
measurement of CBF by SPECT, 905(ab)
radiotrans effects
brain tumors, 1030(ab)
SPECT in cerebrovascular disease, 888(ab)
stereoisomers
Technetium-99m IDA

- Imaging regional cerebral blood flow, 171
- Tumor and tissue blood flow agent, 1031(ab)

Technetium-99m isonitrile
- Deconvolution analysis
- Various liver disease, physiological manifestation, 93(ab)
- Liver transplant function, 451
- Scintigraphy
- Primary biliary cirrhosis, primary sclerosing cholangitis, 1012(ab)

Technetium-99m MAA
- Dosimetry and biological distribution, 100(ab)
- Lung-EG radionuclide venograms
- Thromboembolis, 923(ab)
- Pulmonary embolization detection of sclerotic following scleotherapy, esophageal varices, 95(ab)

Technetium-99m MAG
- I-131 OIH comparison renal imaging, 795
- Renal tubular function, 1052(ab)

Technetium-99m MAG, 1
- Characterization, 93(ab)
- Comparison with I-131 OIH
- Normal subjects and patients, 962(ab)
- Heparin replacement, evaluation, 111
- Relation between structure and renal transport, 894(ab)
- Replacement of I-131 OIH, 571(ab)
- Clearance and renal extraction, 572(ab)

Technetium-99m MDP
- Accumulation in thorax
- Lung cancer, 1032(ab)
- Bone scan
- Osteos metastasis differentiation from benign bone disease, 727(ab)
- Diffuse intrathoracic accumulation, 987(ab)
- Massive uptake in stomach
- Vitamin D intoxication, 219
- Abdominal abscess disease
- Multiphase imaging
- Uterine bluish, 1500(ab)
- Role of radiography/scintigraphy/CT diagnosis and management of chronic osteomyelitis, 978(ab)
- Skull scintigraphy
- Acute mastoid and ear infections, children, 98(ab)

Technetium-99m sulfur colloid, 1076(ab)

- Skeletal disease, 1076(ab)
- Technetium-99m mercaptoacetyltriglycine
- Effect of exercise position during stress testing
- Cardiac and pulmonary thallium kinetics, coronary artery disease, 788

Technetium-99m metallothionein
- Conjugated to Mab
- Tumor localization, 1015(ab)

Technetium-99m microspheres
- Hepatic artery infusion pump, 103(ab)
- Internal dosimetry
- Perirenal cavity, 97(ab)

Technetium-99m monoclonal antibodies
- Experimental thrombi, 1315
- Tumor detection, 685

Technetium-99m pertechnetate
- Glucagon, improvement of abdominal scintigraphy, 103(ab)
- Localization
- Peripheral nerve tumors, 1713
- Salivary gland disease, 1009(ab)
- Stimulated salivary clearance, 306, 308(ab)

Technetium-99m phytate
- Necessity of radionuclide liver scan
- Hepatocellular carcinoma, 1012(ab)

Technetium-99m platelets
- New kit method for labeling, 946(ab)

Technetium-99m potassium sulfate
- Detection, gastrointestinal ulceration, 1(ab)

Technetium-99m Pseudogas
- Lung ventilation studies, 842

Technetium-99m PYP
- Experimental frost bite, 95(ab)

Technetium-99m pyrophosphate
- Demonstration of uptake
- Reversibly injured neonatal myocytes, 93(ab)
- Ischemic gastrocnemius muscle, 103(ab)
- Joint scintigraphy
- Experimental hemorrhage, 246
- Serum MB-creatinine kinase correlation, myocardial infarciton, 994(ab)

Technetium-99m red blood cells
- Cardiac response
- Ambulatory ventricular function monitor, 911(ab)
- Detection of gastrointestinal bleeding
- Glucagon effects, 194(ab)
- Evaluation of gated radionuclide venographic, 990(ab)
- Heat denatured
- Spleen visualization, impaired reticuloendothelial system, 965(ab)
- Hemobilia
- Associated with hepatic artery aneurysms, 491
- Hepatic angiosarcoma, 1861
- Imaging acute gastrointestinal bleeding
- Determination of bleeding rates, 95(ab)
- Labeled RBC
- Occult hemorrhage detection, anticoagulants and, 222(ab)
- Radionuclide venography, 974(ab)
- Red cell surface charge and, 1072(ab)
- Sites of pulmonary hemorrhage
- Cystic fibrosis, 923(ab)
- Venous Doppler directed venography, 1075(ab)

Technetium-99m Sn6SC
- Lymphoscintigraphy
- Prostate, 1034(ab)

Technetium-99m Schill base
- Cations
- Nonreducible, myocardial perfusion agents, 89(ab)

Technetium-99m SQ 30217
- Boronic acid adducts
- Myocardial imaging, 893(ab)

Technetium-99m myocardial perfusion, 893(ab)

Technetium-99m sulfur colloid
- Ascites
- Right pleural effusion and, 1706
- Detection of gastrointestinal bleeding, 95(ab)
- Effect of nifedipine
- Gastric emptying, 905(ab)
- Gastric emptying
- Sex-related differences, 904(ab)
- Ileo-anal anastomosis emptying assessment, 1010(ab)
- Radiopharmaceuticals esophageal transit respiratory effect, 6(ab)
- Tc-99m microalbumin colloid and normal and patient volunteers, 925(ab)

Technetium-99m TBI
- Myocardial imaging, 9(ab)
- Myocardial imaging agent
- Planar and tomographic evaluation, 99(ab)
- TI-201 uptake and heart transplants, 966(ab)

Technetium-99m T-BIN
- Myocardial imaging, 944(ab)

Technetium-99m T-Butylinositrate
- Myocardial distribution
- Reperfusion and hyperemia effects, 1172

Technetium-99m (V) DMS
- Imaging of medullary thyroid carcinoma, 1150

Technologist Section
- See Society of Nuclear Medicine (SNM)

Tellurium fatty acid
- Radioiodinated
- High myocardial specificity, 732.4, 732.6

Testicular torsion
- Scintigraphic findings, 105(ab)

Thorium
- Myocardial phantom lesion, camera-left ventricular distance effects, 1798(ab)

Thorium-201
- Arm vein uptake
- Exercise and, 1353
- Assessment of dipiridamole planar scintigrams, 944(ab)
- Assessment of late redistribution
- Exercise myocardial SPECT, 900(ab)
- Compared to I-123 fatty acid
- Myocardial ischemia, reperfusion, 997(ab)
- Definition of normal limits in stress myocardial rotational tomography, 899(ab)
- Dipiridamole images
- Coronary artery disease, detection and localization, 944(ab)
- Distribution
- Blood-brain barrier disruption and, 736(ab)
- Distribution and washout
- Dipiridamole, planar and SPECT techniques, 943(ab)
- 3-D myocardial distributions
- Artificial intelligence approach, 1005(ab)
- Effect of early redistribution
- Myocardial perfusion studies, 95(ab)
- Effect of exercise position during stress testing
coronary artery disease, 788
exercise electrocardiography and prediction of death, myocardial infarction, and chest pain, 1842
exercise imaging, redistribution abnormalities, 997(ab)
exercise planar scintigraphy quantitation of patient defects, 953(ab)
exercise scintigraphy planar thallium defects, 1273 prognostic stratification of asymptomatic patients, 954(ab)
180° exercise SPECT diagnostic accuracy, chest pain syndrome, 999(ab)
exercise testing after myocardial testing, 967(ab) fixed perfusion defects PET, identified viable myocardial segments, 932(ab)
imaging dipyridamole, clinical decision making, 132 interpreting images using fuzzy clustering, 928(ab)
 ischemia coronary artery disease, significance of exertional angina, 998(ab)
kinetics malignant tumors, 1033(ab) myocardium, rabbit, 66
leg muscle perfusion study SPECT, 1035(ab)
localization of parathyroid tumors optimized dual-isotope, 962(ab) lower limb perfusion study
reconstructive vascular surgery and, 1035(ab) myocardial clearance of peak exercise heart rate effects on, 26 myocardial imaging dipyridamole-induced coronary vasodilation, 31 myocardial rubidium extraction and effects of altered perfusion and hypoxia, 965(ab)
myocardial scintigrams quantitative analysis, 17 myocardial scintigraphy discrete sub-aortic stenosis, 1069(ab) myocardial washout rate, 943(ab) oral administration assessment of portal-systemic circulation, 957(ab) parathyroid scintigraphy localization, ectopic and transplanted parathyroid glands, 963(ab)
peak activity parathyroid imaging, image reregistration technique, 965(ab)
perfusion defects acute myocardial infarction, 1005(ab) per-rectal administration portal-systemic circulation, 1010(ab) planar myocardial perfusion imaging computer modeling of, 653 postinfarct ischemia prognostic implication, 926(ab) prognosis patients with normal Tl-201 images, 954(ab) quantitation of myocardial rotational tomography, 899(ab) radioactive distribution brain, after CSF injection, 1029(ab) redistribution normal males, 996(ab)
“redistribution” explanation, 996(ab) redistribution postischemia effect of eating, 953(ab) regional myocardial extraction compared with IPPA, 934(ab) regional myocardial fatty acid uptake cardiomyopathy, autoradiography, 933(ab) rest imaging risk stratification, after acute myocardial infarction, 968(ab) scintigraphic quantitation regional flow disparity, 75 scintigraphy coronary arteriography, prolonged postexercise ST segment depression, 998(ab) recurrent medullary thyroid carcinoma, 1564 serial SPECT assessment of therapy, acute myocardial infarction, 996(ab) sex-specific criteria for uptake myocardial, 1837 SPECT comparison with planar imaging, coronary artery disease, 999(ab) exercise loading, 999(ab) quantitation of, 1797(ab) SPECT images knowledge-based system for, 1798(ab) SPECT imaging myocardial contusion, 998(ab) SPECT using oral dipyridamole assessment of coronary artery stenosis, before transluminal angioplasty, 944(ab) stress-redistribution SPECT localization, coronary artery disease, 997(ab) stress test reverse redistribution pattern, coronary angiograms, 1377(le) submaximal exercise heart rate significance of slow myocardial washout rate, 953(ab) subtraction scanning hyperparathyroidism in renal osteodystrophy, 580(ab) technetium and false-negative subtraction scintigraphy, 564(le) testing of asymptomatic patients positive EKG tests, 998(ab) thyroglobulin and I-131 uptake differentiated carcinoma, thyroidectomy, 886(ab) thyroid carcinoma diagnosis and staging, 887(ab) tissue uptake and phantom studies parathyroid imaging limits, 1262 total-body scintigraphy thyroid carcinoma, 1854 transluminal coronary angioplasty, 900(ab) transluminal coronary angioplasty parameters, 900(ab) uptake blood flow relations, global left ventricular, 641 "upward creep" of the heart, 899(ab) variability of half life rest to exercise, 997(ab) Thallium-201 chloride F(ab')2 and imaging of melanoma, 1022(ab) myocardial perfusion imaging, 146, 147(le) Thallium-201 diethyldithiocarbamate tracer for local cerebral blood flow comparison, isopropylidoamphetamine and iodoantipyrine, 913(ab) Thallium-201 pertechnetate subtraction scintigraphy adenomatous and hyperplastic parathyroid glands, 963(ab)
Thallium planar imaging defects exercise TI-201 scintigraphy, 1273 Therapeutic nuclear medicine Cu-67 labeled antibodies, 1042(ab) cutaneous T-cell lymphoma murine monoclonal antibodies, 903(ab) hyperthyroidism radiodine therapy for, 309(le) I-131 MIBG neuroadrenergic tumor avidity, significance for therapy, 948(ab) I-131 monoclonal antibodies 19-9/anti-CEA and OC 125, 1019(ab) I-131 metastatic well-differentiated thyroid carcinoma, 1519 intra-articular Yttrium-90 therapy chronic hemophilic synovitis, 987(ab) monoclonal antibodies to CEA cancer immunoimaging, 897(ab) P-32 therapy cystic brain tumors, 1503(le) peritoneal cavity internal dosimetry, 979(ab) preparation of Yt-90-labeled antibodies patient use, 959(ab) radiation dosimetry cystic-type tumors, 1501(le) radioactive iodine uptake breasts, 150(ab) radiolabeled lymphocytes allograft rejections, 896(ab) Sm-153 chelates biolocalization, 915(ab)
Sm-153 EDTMP treatment spontaneous bone tumors, 986(ab) Te-99m-metallothionein conjugated B72.3 antibodies, 896(ab) thyroid cancer I-131 diagnostic dose, 1764 Thiol mapping of redox status C-13 NMR, 91(ab)
Thoma, Jr., George E. JNM founding editor looks to future of nuclear medicine and medical education, N1097 Thrombolysis intracoronary effects on global left ventricular function, 478 Thrombosis deep vein In-111 platelets, 1036(ab) deep venous In-111 leukocyte scintigraphy, 631 effect of vitamin E platelet and fibrinogen deposition, 947(ab) evaluation of In-111-labeled antifibrin antibody, 975(ab) I-125 IPM platelet membrane functions, 1046(ab) imaging Te-99m antifibrin, 975(ab) lower extremity deep venous In-111 platelet images, 1035(ab) lung-leg radionuclide venograms, 923(ab) residual coronary thrombi myocardial infarction, In-111 antifibrin Mab, 910(ab)
Thrombus
venous
routine lung scintigraphy, lower extremity
Xe-133 imaging, 974(ab)

Thrombus
fresh venous
In-111 and I-131 monoclonal antibody imaging, 941(ab)
location
Ga-67 deferoxamine-diaethyldisulfide labeled with Tc-99m, 95(b)

Thrombus
Thyroid
efficiency
I-131 and I-131 MIBG, 1071(ab)

Thyroid
automated RIA
thyroxin and free thyroxin assays, 1623 cancer
I-131 treatment, 1207 carcinoma
calculations in biochemical parameters during complete hormone deficiency, 1528 diagnosis and staging with TI-201, euthyroid patient, 887(ab)
I-131 rational dose therapy, 1519 I-131 therapy, cerebral edema following, 637 medullary cell uptake of I-131 MIBG, 1071(ab)
TI-201 total-body scintigraphy, 1854 commercial hippuran
radiochemical purity and in vitro stability, 850 determination of tracer dose of I-131 metastatic thyroid cancer, small source phantom, 886(ab) efficacy of radionuclide thyroid scan evaluation of upper mediastinal mass, intrathoracic goiter, 887(ab)

Hyperthyroidism
radiodine therapy for, four-hour radiodine uptake determination prior to, 309(ab) hyperthyroidism and Hashimoto's thyroiditis iodine uptake, elderly women, 909(ab)
I-131 cancer staging, 886(ab) medullary carcinoma
I-131 MIBG imaging, 1858 MIBG uptake, multiple endocrine neoplasia, 1096(ab) Tc-99m (V) DMS and I-131 MIBG in, 1150 metastatic calcification
bone scan, primary hyperparathyroidism, 373 metastatic cancer
I-131 diagnostic dose for imaging, 1764 radioactive iodine uptake, 150(ab) radioiodine uptake, 428 recurrent medullary carcinoma
TI-201 scintigraphy, 1564 spurious cancer metastasis
I-131 metastases survey, 634 thyroglobulin and I-131 uptake differentiated carcinoma, thyroidectomy, 886(ab)
triiodothyronine in serum
diagnostic value, 1702

Thyroid gland
volume
high resolution ultrasonic scanner, 1475

Thyroxine (T-4)
deficiency
tyroid cancer, 1528

Tinning agent
stannous glucosecontenate
blood cell labeling, 1052(ab)

Tissue contrast
MRI pulse sequence parameters simulation procedure, 281
Tomographic reconstruction noise
PET sensitivity, 1790(e)

Tomography
double isotope emission
immunoscinctography, hepatocellular carcinoma, 1022(ab)
black blood pool left ventricular function and, 1916

Tomography, x-ray
circular harmonic transform algorithm PET, 1003(ab)

Tracheobronchoplasty
muscular clearance in radioaerosol, 1397

Triglyceride
radiodinated liver imaging agent, 1046(ab)

Triiodothyronine
determination
free diagnostic value in serum, 1702

Tuberculosis enteritis
In-111 oxine in detection of, 1071(ab)

Tumor
brain
grading, C-11-L-methionine PET, 890(ab) breast cancer, 305(ab)
carcinembryonic antigens Lewis-negative individuals, 1039(ab)
carcinoid
I-131 MIBG Scintigraphy in, 1691 colon and gastric cancer xenografts IgM monoclonal antibodies, 1022(ab) differential uptake
Ga-67-labeled liposomes, 1300 effect of local hyperthermia
In-111 macrophage distribution, 1015(ab) Ga-67 accumulation in, 1215 gamma camera imaging
NMR and, Gd-labeled monoclonal antibodies, 829 hapten antibody complexes immunoscinctography, 95(ab)
I-123 IMP demonstration of metastatic melanoma, 971(ab) I-131 cancer staging, 886(ab) imaging
Indium-111 phospholipid vesicles, 971(ab) index of aggressivity
glucose utilization, non-glomatos neoplasms, 90(ab) intra-arterial and intravenous [14C]BCNU pharmacokinetics, evaluated by PET, 775 localization
Tc-99m MT conjugated to MAb, 1015(ab) malignant
abnormal uptake of Tc-99m DMSA, 1032(ab) TI-201 kinetics in, 1033(ab) marrow involvement
lymphoma, magnetic resonance imaging, 964(ab) metabolic and hemodynamic studies of gliomas PET, 859(ab) metastatic melanoma detection
In-111 DTPA antibody, 1019(ab)
metastatic thyroid cancer determination of tracer dose of I-131, 886(ab)
monoclonal "tumor associated" antibodies factors affecting uptake, 92(ab)
mutant anti-ARS MAb pharmacokinetics and imaging, 1023(ab)
neuroendocrine
uptake of I-131 MIBG, 908(ab)
neurofibroma localizations of Tc-99m DTPA, 143(ab)
Ontology emphasizes strength of nuclear medicine in tissue characterization;
European Nuclear Medicine Congress 1986 scientific highlights, N1653 osteogenic sarcoma chemotherapy, Tc-99m HMID serial bone scans, 987(ab)
osteosarcoma reactivity of monoclonal antibodies, 921(ab) ovarian cancer immunotherapy with viral oncosyate, In-111 leukocytes, 942(ab) peripheral nerve
Tc-99m pertechnetate in, 1713 phantom models
miniature thermoluminescent dosimeter, 1308 prostate
Tc-99m DMSA uptake, 1223(ab), 1224(ab) radiopharmaceutical delivery bifunctional chelates, 938(ab) sacral scintigraphic features, 627 size monoclonal antibody uptake and, 422 size effects monoclonal antibody uptake, 1789(ab) soft tissue imaging with Tc-99m DMS, 1033(ab) solid
I-131 MIBG scanning, children, 620 SPECT imaging with para-axial neurobfibransomatosis, 932(ab) spontaneous bone
Sm-153 EDTMP treatment, 986(ab)

Tumor necrosis factor
radiolabeled potential for tumor imaging, 970(ab)

Tumor perfusion
evaluation by propranolol hydrochloride sarcoma, mouse, 243

Tumor-seeking agents
abnormal uptake
malignant tumors, 1032(ab) antibody conjugation immunoscinctography, 1040(ab) anti-human parathyroid monoclonal antibodies evaluation, 958(ab) biodistribution
In-111 antibody DTPA, ester bonds, 959(ab) breast cancer, 305(ab) carcinoid tumors, 1691 C-11 thymidine
PET, 1033(ab) Cu-67 labeled antibodies, 1042(ab) curative radioimmunotherapy novel strategy, 943(ab) cutaneous T-cell lymphoma murine monoclonal antibodies, radioimmunodetecion, 903(ab) dosimetry in metabolic radiotherapy I-131 MIBG, neuroblastoma and phaeochromocytoma, 100(ab)
DTPA attachment monoclonal antibodies, 1041(ab) estrogen-receptor radiotracer, 916(ab) F-18 fluorodeoxyfucose new tracer of glycoprotein metabolism, 983(ab) Ga-67 accumulation in tumors, 1215

1988
The Journal of Nuclear Medicine
infected renal cyst, 1147

Urinary tract
duplication
DMSA scintigraphy in, 1154
obstruction
functional imaging, 581(ab)
peristaltis
routine renography, 581(ab)

Urinary extravasation into scrotum, 807

Uterus
blush
multiphase bone imaging, 51
multiphase imaging, 1500(le)
pregnancy
bone and gallium scintigraphy, 370

Venography
lung-leg
thrombosis, 923(ab)

Ventriculography
lung-leg
Xenon-133

Ventriculography
first pass radionuclide angiography
multiwire gamma camera compared to multicrystal camera, 91(ab)
left ventricular volume measurement
first-pass radionuclide angiography, 912(ab)
LVEF analyzed frame and list mode
atrial and premature beats, 935(ab)
right and left ventricular ejection fraction correlation, volume measurements, 991(ab)

Ventriculography, radionuclide
management of renal transplant candidates,
579(ab)

Vesicoureteral reflux
diagnosis
factor analysis, 581(ab)
mimicking of obstructive uropathy, 304(le)

Veterans Administration
Veterans Administration appoints new director of nuclear medicine service, N168

Video densitometry
personal computer, 549

Vitamin B6
deficiency
effects on neurotransmission, relation to epilepsy, 969(ab)

Vitamin B12
levels
racial dependence, 892(ab)
Schilling test replacement
resorption test, 892(ab)

Vitamin D
intoxication
massive uptake of Tc-99m MDP in stomach and, 219

serum metabolites
clinical evaluation of, 1040(ab)

W
Wahl, Richard L.
Richard Wahl receives Tetalman Award for monoclonal antibody research, N1388

Walker 256 carcinosarcoma
N-13 glutamate uptake
single-dose irradiation, 1604

Water
partition coefficient values
estimation of ICBF and ICMRO2 in PET, 941(ab)

Wegener's granulomatosis
spleen
In-111 scintigraphy in, 1864

Wolff-Parkinson-White syndrome
Fourier analysis
epicardial pacing, 993(ab)

X

Xenon-133
background correction
simplified ventilation index, 951(ab)
benign prostatic hypertrophy
impotence relations, 1036(ab)
123-I-lodoamphetamine and
SPECT and PET, chronic cerebral infarcts, 888(ab)
inhalation
measurement of regional liver blood flow, 1012(ab)
single dose multi-step method
muscle blood flow response differences, 1035(ab)
skeletal muscle blood flow
maximum and submaximum exercise, heart failure, 993(ab)
suspected pulmonary embolism, 1391

TC-99m DTPA alternative, tissue viability and flow direction, 975(ab)

Xenon, radioactive
differential method for disposal, 1374(le)

Xenon scans
gated
right ventricular function, 609

U
Ulcer
detection
TC-99m sulfur colloid, potassium sucrose, 1(ab)

Ultrasound scanner
high resolutional
volume of thyroid gland, 1475

Ultrasound
diagnostic
correlation of radionuclide imaging, scrotal diseases, 1774

In-111 leukocyte advantages over

Ga-67 monoclonal antibody
human osteosarcoma, 1021(ab)

GD2 specific I-131 labeled monoclonal antibodies
melanoma, osteogenic sarcoma and neuroblastoma, 881(ab)

I-123 and I-131 MIBG scans
clinical contribution, 947(ab)

I-123 IMP
malignant tumors, 1033(ab)

I-131 MIBG
uptake by neuroendocrine tumors, 908(ab)

I-131 MIBG imaging in neuroblastoma, 947(ab)

I-131 monoclonal antibodies
19-9/anti-CEA and OC 125, 1019(ab)
route of administration, colorectal cancer, 902(ab)

In-111 anti-CEA
correlation with surgical samples, 1023(ab)

In-111 lymphocytes
expansion with interleukin-2, 970(ab)

In-111 monoclonal antibodies
attempts to saturate hepatic clearance mechanism, 921(ab)

In-111 phospholipid vesicles
human tumor imaging, 971(ab)

iodination of monoclonal antibodies, 1890
kit-form analogs, 256

melanotic and amelanotic B16 melanoma, 1045(ab)

pheochromocytoma, 1222(le)

radioimmunotherapy
I-131 monoclonal antibodies, colon carcinoma xenografts, 1019(ab)

radioabeled tumor necrosis factor
imaging, 970(ab)

186-Re(Sn)HEDP
new agent, metastatic carcinoma to bone, 948(ab)

second-clearance
radioimmunodetection of cancer, 897(ab)

Sm-153 chelates
biolealization, 915(ab)

TC-99m DMS
soft tissue tumors, 1033(ab)

TC-99m DTPA
neurofibroma, 143(le)

TI-201-perchethenate subtraction scintigraphy
adenomatous and hyperplastic parapharyngial glands, 963(ab)

Tungsten-178
Ta-178 and
dosimetry, adults and children, 1009(ab)

Tungsten-178/Tantalum-178 generator
improved, 1043(ab)

Tyrosine
enzymatic synthesis and biodistribution
tumor-bearing animals, 104(ab)

measurement of protein synthesis
brain, PET, 1049(ab)

U
Ulcer
detection
TC-99m sultam, potassium sucrose sulfate, 1(ab)

Ultrasound scanner
high resolutional
volume of thyroid gland, 1475

Ultrasound
diagnostic
correlation of radionuclide imaging, scrotal diseases, 1774

In-111 leukocyte advantages over

579(ab)

Vesicoureteral reflux
diagnosis
factor analysis, 581(ab)
mimicking of obstructive uropathy, 304(le)

Veterans Administration
Veterans Administration appoints new director of nuclear medicine service, N168

Video densitometry
personal computer, 549

Vitamin B6
deficiency
effects on neurotransmission, relation to epilepsy, 969(ab)

Vitamin B12
levels
racial dependence, 892(ab)
Schilling test replacement
resorption test, 892(ab)

Vitamin D
intoxication
massive uptake of Tc-99m MDP in stomach and, 219

serum metabolites
clinical evaluation of, 1040(ab)

W
Wahl, Richard L.
Richard Wahl receives Tetalman Award for monoclonal antibody research, N1388

Walker 256 carcinosarcoma
N-13 glutamate uptake
single-dose irradiation, 1604

Water
partition coefficient values
estimation of ICBF and ICMRO2 in PET, 941(ab)

Wegener's granulomatosis
spleen
In-111 scintigraphy in, 1864

Wolff-Parkinson-White syndrome
Fourier analysis
epicardial pacing, 993(ab)

X

Xenon-133
background correction
simplified ventilation index, 951(ab)
benign prostatic hypertrophy
impotence relations, 1036(ab)
123-I-lodoamphetamine and
SPECT and PET, chronic cerebral infarcts, 888(ab)
inhalation
measurement of regional liver blood flow, 1012(ab)
single dose multi-step method
muscle blood flow response differences, 1035(ab)
skeletal muscle blood flow
maximum and submaximum exercise, heart failure, 993(ab)
suspected pulmonary embolism, 1391

TC-99m DTPA alternative, tissue viability and flow direction, 975(ab)

Xenon, radioactive
differential method for disposal, 1374(le)

Xenon scans
gated
right ventricular function, 609
Itsuo Yamamoto receives Berson-Yalow Award for radioassay research. N742

Yttrium-90

colonic cancer xenografts
radioimmunotherapy, anti-CEA antibody, 897(ab)
intra-articular
chronic hemophilic synovitis, 987(ab)

serial distribution of absorbed dose
small sources, 1007(ab)
Yttrium-90 antibodies
preparation for patient use, 959(ab)

Z

Zirconium-89
production for antibody imaging
PET, 983(ab)
Information for Authors

EDITORIAL POLICY
The Journal of Nuclear Medicine publishes several types of original articles in the clinical and basic sciences, case reports, technical notes, special contributions, editorials, letters to the editor, news items pertinent to the practice of the field, and articles of general medical interest. Manuscripts submitted must be original, including illustrations and tables, and not under consideration by another publication.

MANUSCRIPT SUBMISSION
Submit all manuscripts to: Thomas P. Haynie, MD, The Journal of Nuclear Medicine, Office of Special Publications, The University of Texas M. D. Anderson Hospital, 6723 Bertner Avenue, Houston, TX 77030; (713)792-6015. Send an original and two copies of the manuscript with three sets of unmounted illustrations (glossies, no smaller than 3½ × 5″ or larger than 8 × 10″).

COPYRIGHT
In compliance with the Copyright Revision Act of 1976, effective January 1, 1978, the following written statement must accompany all submissions: "Upon acceptance by The Journal of Nuclear Medicine, all copyright ownership of the article (complete title of the article in this space) is transferred to The Society of Nuclear Medicine. On behalf of any and all co-authors, I accept the responsibility for release of any part or all of the material contained within the article noted above. The undersigned stipulates that the material submitted to The Journal of Nuclear Medicine is original and has not been submitted to another publication for concurrent consideration." Copyright requirement does not apply to work prepared by United States government employees as part of their official duties.

REVIEW PROCEDURE
Submitted manuscripts are reviewed for content on the basis of originality, significance, adequacy of documentation, reader interest, and composition. All manuscripts judged suitable for review by the editorial staff are reviewed by a minimum of two referees. Accepted manuscripts are subject to editorial revision for scientific accuracy and for clarity in the office of the Editor.

MANUSCRIPT FORMAT
Begin each manuscript component on a new page in the following order: title page, abstract, text, footnotes, acknowledgments, references, tables (each on a new page), and legends for illustrations.

1. Every page must be typed double spaced, including title page, abstract, text, references, legends, acknowledgments, and footnotes, on 8½ × 11″ reusable white bond (8 ½ × 11ʺ). One-inch margins on all sides of typewritten pages. Type at least double line spacing and limit reproductive line length to 50 words.
2. Leave a 2-in. margin on all sides of typewritten pages.
3. Reference numbers in the text should be underlined and in parentheses. Do not underline in the reference list.
4. Paragraphs should begin with an indentation of at least five spaces.
5. Number all pages at the top right-hand side with names of the author(s) or title of the article.
6. Handwritten changes are not acceptable.
7. Papers must be written in English.
8. References in the text should not be made to institutions or locales except when germane to that particular article.
9. Generic names should be used. Manufacturers of instruments or radiopharmaceuticals should not be named in the manuscript unless their inclusion is absolutely essential to the content. When necessary, however, manufacturers should be identified by footnotes. Consecutive order of footnote symbols is: *, †, ‡.

TITLE PAGE
The title should be as short as possible, with a maximum of 72 characters including spaces. The title page should include: the first and last names of all authors; departmental and institutional affiliations of all authors; and complete mailing address, telephone number, and zip code of the author responsible for correspondence and reprints.

ABSTRACT
Abstracts must be limited to 150 words and typed on a separate page.

REFERENCES
References must be typed double spaced on a separate sheet and numbered consecutively as they are cited in the text. References included in a table or illustration are also numbered sequentially with those in the text. When more than three authors appear, the additional authors are listed as “et al.” The Journal uses the Index Medicus style for references. Journal names are abbreviated according to the List of Journals Indexed in Index Medicus. Sample references are:

TABLES
Tables should be self-explanatory and supplement, not duplicate, the text. Each table must be cited in numerical order in the text and typed on a separate sheet of paper after the references. Number the tables consecutively with an arabic number following the word TABLE. The titles should be descriptive, brief, and centered in upper and lower case letters. Include explanatory material in the footnotes or the text. Place horizontal lines below the title, below column headings, and at the end of the table. Do not use vertical rules.

ILLUSTRATIONS
Illustrations should be limited to those which clarify and augment the text. Since imaging is one of the major aspects of nuclear medicine, the selection of high-quality halftone illustrations is of paramount importance. High-contrast glossy prints should be submitted instead of film. Original line drawings and graphs are preferred for optimal reproduction and should be rendered professionally on white drawing paper in black India ink. Template or typewriter lettering should be used. No hand drawings, typewritten art, or computer-generated art will be accepted. Figures of inferior quality will be returned to the author for correction and replacement. Details to be emphasized or crop marks should be indicated on a tissue overlay. Each illustration must be numbered and cited in order in the text. The following information should be typed on a gummed label and affixed to the back of each illustration: figure number, senior author, title of manuscript, and arrow indicating "top." Authors are responsible for the costs of color reproduction. All illustrations submitted will become property of the SNM and will not be returned unless specifically requested by the author upon submission of manuscript.

LEGENDS FOR ILLUSTRATIONS
Submit a separate legend page with descriptive paragraphs for each figure, typed double spaced in numerical order with an arabic number following the word FIGURE. If illustrations have been published previously, authors are responsible for obtaining permission to reproduce them from both the original author and publisher. The source must be cited in the references and the following credit line must appear in the legend: (Reprinted by permission of Ref. X.) All permission releases must be submitted to the Editor at the time of acceptance.

UNITS AND ABBREVIATIONS
Nomenclature, units, and abbreviations should conform to IUPAC recommendations and Systeme Internationale (SI). Chemical formulae follow the recommendations of the American Chemical Society.
<table>
<thead>
<tr>
<th>Advertiser</th>
<th>Page Number</th>
<th>Reader Service No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atomic Energy of Canada, Ltd.</td>
<td>11A</td>
<td>7</td>
</tr>
<tr>
<td>Kanata, Ont., Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atomic Products</td>
<td>IBC</td>
<td>22</td>
</tr>
<tr>
<td>Shirley, NY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canberra</td>
<td>21A</td>
<td>16</td>
</tr>
<tr>
<td>Meriden, CT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capintec, Inc.</td>
<td>17A</td>
<td>12</td>
</tr>
<tr>
<td>Ramsey, NJ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Cardiology Publishing, Inc.</td>
<td>24A</td>
<td>18</td>
</tr>
<tr>
<td>Mawah, NJ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diversified Diagnostix Products, Inc.</td>
<td>10A</td>
<td>6</td>
</tr>
<tr>
<td>Houston, TX</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elscint, Inc.</td>
<td>9A</td>
<td>5</td>
</tr>
<tr>
<td>Boston, MA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>European Nuclear Medicine Congress 1987</td>
<td>30A</td>
<td>20</td>
</tr>
<tr>
<td>Budapest, Hungary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>International CIS</td>
<td>22A</td>
<td>17</td>
</tr>
<tr>
<td>Yvelines-Cedex, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>JRT Associates</td>
<td>32A</td>
<td>21</td>
</tr>
<tr>
<td>Riverdale, NY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medi-Physics, Inc.</td>
<td>IFC, IA, OBC</td>
<td>1, 23</td>
</tr>
<tr>
<td>Richmond, CA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEDX</td>
<td>15A</td>
<td>10</td>
</tr>
<tr>
<td>Rolling Meadows, IL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Products</td>
<td>33A</td>
<td>101-102</td>
</tr>
<tr>
<td>Norland Corporation</td>
<td>12A</td>
<td>8</td>
</tr>
<tr>
<td>Fort Atkinson, WI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novo Diagnostic Systems</td>
<td>7A</td>
<td>3</td>
</tr>
<tr>
<td>Wilton, CT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nuclear Associates</td>
<td>2A</td>
<td>2</td>
</tr>
<tr>
<td>Carle Place, NY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nuclear Data, Inc.</td>
<td>20A</td>
<td>15</td>
</tr>
<tr>
<td>Schaumberg, IL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positron Corporation</td>
<td>16A</td>
<td>11</td>
</tr>
<tr>
<td>Houston, TX</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Siemens Medical Systems, Inc.</td>
<td>19A</td>
<td>14</td>
</tr>
<tr>
<td>Iselin, NJ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SNM/ACNP SPECT '87</td>
<td>8A</td>
<td>4</td>
</tr>
<tr>
<td>SNM Winter Meeting</td>
<td>24A</td>
<td>19</td>
</tr>
<tr>
<td>Squibb Diagnostics</td>
<td>13A, 14A</td>
<td>9</td>
</tr>
<tr>
<td>New Brunswick, NJ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syncor International</td>
<td>18A</td>
<td>13</td>
</tr>
<tr>
<td>Sylmar, CA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>